US20190160150A1 - Acth for treatment of acute respiratory distress syndrome - Google Patents
Acth for treatment of acute respiratory distress syndrome Download PDFInfo
- Publication number
- US20190160150A1 US20190160150A1 US16/251,363 US201916251363A US2019160150A1 US 20190160150 A1 US20190160150 A1 US 20190160150A1 US 201916251363 A US201916251363 A US 201916251363A US 2019160150 A1 US2019160150 A1 US 2019160150A1
- Authority
- US
- United States
- Prior art keywords
- acth
- analog
- fragment
- aggregate
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 title claims abstract description 135
- 238000011282 treatment Methods 0.000 title claims abstract description 54
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 title abstract description 130
- 201000000028 adult respiratory distress syndrome Diseases 0.000 title abstract description 128
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims abstract description 246
- 101800000414 Corticotropin Proteins 0.000 claims abstract description 209
- 229960000258 corticotropin Drugs 0.000 claims abstract description 207
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 claims abstract description 205
- 238000000034 method Methods 0.000 claims abstract description 114
- 239000003997 corticotropin derivative Substances 0.000 claims description 220
- 239000000203 mixture Substances 0.000 claims description 98
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 90
- 238000009472 formulation Methods 0.000 claims description 62
- 241000282414 Homo sapiens Species 0.000 claims description 31
- 238000002347 injection Methods 0.000 claims description 19
- 239000007924 injection Substances 0.000 claims description 19
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- 238000013270 controlled release Methods 0.000 claims description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 14
- 230000002829 reductive effect Effects 0.000 claims description 14
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 230000000541 pulsatile effect Effects 0.000 claims description 9
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 8
- 239000003862 glucocorticoid Substances 0.000 claims description 8
- 239000007943 implant Substances 0.000 claims description 8
- 230000002035 prolonged effect Effects 0.000 claims description 8
- 102000004877 Insulin Human genes 0.000 claims description 7
- 108090001061 Insulin Proteins 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 7
- 229940125396 insulin Drugs 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 6
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 claims description 6
- NSMXQKNUPPXBRG-SECBINFHSA-N (R)-lisofylline Chemical compound O=C1N(CCCC[C@H](O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-SECBINFHSA-N 0.000 claims description 6
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 6
- 102400000739 Corticotropin Human genes 0.000 claims description 6
- 108010091893 Cosyntropin Proteins 0.000 claims description 6
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 claims description 6
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 6
- 101000773743 Homo sapiens Angiotensin-converting enzyme Proteins 0.000 claims description 6
- 101800004937 Protein C Proteins 0.000 claims description 6
- 101800001700 Saposin-D Proteins 0.000 claims description 6
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 6
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 6
- 229960000711 alprostadil Drugs 0.000 claims description 6
- 229940125388 beta agonist Drugs 0.000 claims description 6
- 229960004436 budesonide Drugs 0.000 claims description 6
- 229960003957 dexamethasone Drugs 0.000 claims description 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 6
- 229960002897 heparin Drugs 0.000 claims description 6
- 229920000669 heparin Polymers 0.000 claims description 6
- 229960004125 ketoconazole Drugs 0.000 claims description 6
- 229950011606 lisofylline Drugs 0.000 claims description 6
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 6
- 238000011903 nutritional therapy Methods 0.000 claims description 6
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims description 6
- 229960000856 protein c Drugs 0.000 claims description 6
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 6
- 208000028399 Critical Illness Diseases 0.000 claims description 5
- 230000003111 delayed effect Effects 0.000 claims description 5
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 claims description 5
- 229960001123 epoprostenol Drugs 0.000 claims description 5
- 238000005399 mechanical ventilation Methods 0.000 claims description 5
- 229960004584 methylprednisolone Drugs 0.000 claims description 5
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 4
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 4
- 206010036105 Polyneuropathy Diseases 0.000 claims description 4
- 229960004495 beclometasone Drugs 0.000 claims description 4
- 229960002537 betamethasone Drugs 0.000 claims description 4
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 229960001680 ibuprofen Drugs 0.000 claims description 4
- 229960002009 naproxen Drugs 0.000 claims description 4
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 4
- 229960005489 paracetamol Drugs 0.000 claims description 4
- 229960005205 prednisolone Drugs 0.000 claims description 4
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 4
- 229960004618 prednisone Drugs 0.000 claims description 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 4
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims description 4
- 229960005294 triamcinolone Drugs 0.000 claims description 4
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 4
- BMLMGCPTLHPWPY-REOHCLBHSA-N (4R)-2-oxo-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSC(=O)N1 BMLMGCPTLHPWPY-REOHCLBHSA-N 0.000 claims description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 3
- 102000001617 Interferon Receptors Human genes 0.000 claims description 3
- 108010054267 Interferon Receptors Proteins 0.000 claims description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 3
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 3
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 3
- 229960004308 acetylcysteine Drugs 0.000 claims description 3
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 3
- 230000000202 analgesic effect Effects 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 235000006708 antioxidants Nutrition 0.000 claims description 3
- 229940124748 beta 2 agonist Drugs 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 210000000233 bronchiolar non-ciliated Anatomy 0.000 claims description 3
- XXZSQOVSEBAPGS-DONVQRBFSA-L cisatracurium besylate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1.[O-]S(=O)(=O)C1=CC=CC=C1.C1=C(OC)C(OC)=CC=C1C[C@H]1[N@+](CCC(=O)OCCCCCOC(=O)CC[N@+]2(C)[C@@H](C3=CC(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=CC=2)(C)CCC2=CC(OC)=C(OC)C=C21 XXZSQOVSEBAPGS-DONVQRBFSA-L 0.000 claims description 3
- 229960000970 cisatracurium besylate Drugs 0.000 claims description 3
- 239000002934 diuretic Substances 0.000 claims description 3
- 230000001882 diuretic effect Effects 0.000 claims description 3
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 3
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims description 3
- 229940102223 injectable solution Drugs 0.000 claims description 3
- 239000003158 myorelaxant agent Substances 0.000 claims description 3
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 3
- 239000006014 omega-3 oil Substances 0.000 claims description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
- 229940044601 receptor agonist Drugs 0.000 claims description 3
- 239000000018 receptor agonist Substances 0.000 claims description 3
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 3
- 229960000672 rosuvastatin Drugs 0.000 claims description 3
- 229960002052 salbutamol Drugs 0.000 claims description 3
- 239000000932 sedative agent Substances 0.000 claims description 3
- 230000001624 sedative effect Effects 0.000 claims description 3
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 3
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 3
- 238000009423 ventilation Methods 0.000 claims description 3
- 102000017975 Protein C Human genes 0.000 claims 2
- 102000002262 Thromboplastin Human genes 0.000 claims 2
- 108010000499 Thromboplastin Proteins 0.000 claims 2
- 229940012414 factor viia Drugs 0.000 claims 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 abstract description 306
- 102100027467 Pro-opiomelanocortin Human genes 0.000 abstract description 207
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 72
- 239000012071 phase Substances 0.000 description 66
- -1 complex Substances 0.000 description 36
- 229940036707 acthar Drugs 0.000 description 32
- 239000008194 pharmaceutical composition Substances 0.000 description 32
- 230000002354 daily effect Effects 0.000 description 31
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 30
- 239000002552 dosage form Substances 0.000 description 26
- 239000003814 drug Substances 0.000 description 25
- 239000000499 gel Substances 0.000 description 25
- 239000006185 dispersion Substances 0.000 description 24
- 229940079593 drug Drugs 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- 210000004072 lung Anatomy 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 239000002158 endotoxin Substances 0.000 description 15
- 229960000890 hydrocortisone Drugs 0.000 description 15
- 239000000651 prodrug Substances 0.000 description 15
- 229940002612 prodrug Drugs 0.000 description 15
- 230000028327 secretion Effects 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 239000003826 tablet Substances 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 239000002775 capsule Substances 0.000 description 12
- 239000012530 fluid Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 206010069351 acute lung injury Diseases 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 210000000440 neutrophil Anatomy 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 10
- ZOEFCCMDUURGSE-CQVUSSRSSA-N cortrosyn Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)C(N)CO)C1=CC=C(O)C=C1 ZOEFCCMDUURGSE-CQVUSSRSSA-N 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 229920000392 Zymosan Polymers 0.000 description 9
- 239000000443 aerosol Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000003085 diluting agent Substances 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 239000000902 placebo Substances 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 239000003381 stabilizer Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 101500024079 Homo sapiens Corticotropin Proteins 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 230000002238 attenuated effect Effects 0.000 description 7
- ZOEFCCMDUURGSE-SQKVDDBVSA-N cosyntropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 ZOEFCCMDUURGSE-SQKVDDBVSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 230000001817 pituitary effect Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 230000009885 systemic effect Effects 0.000 description 7
- 102000004890 Interleukin-8 Human genes 0.000 description 6
- 108090001007 Interleukin-8 Proteins 0.000 description 6
- 208000004852 Lung Injury Diseases 0.000 description 6
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 206010069363 Traumatic lung injury Diseases 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 238000002648 combination therapy Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 6
- 229940096397 interleukin-8 Drugs 0.000 description 6
- 231100000515 lung injury Toxicity 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 238000010149 post-hoc-test Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000010922 spray-dried dispersion Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 108010006654 Bleomycin Proteins 0.000 description 5
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 5
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 108090000950 Melanocortin Receptors Proteins 0.000 description 5
- 102000004378 Melanocortin Receptors Human genes 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 5
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 235000019325 ethyl cellulose Nutrition 0.000 description 5
- 229920001249 ethyl cellulose Polymers 0.000 description 5
- 230000016784 immunoglobulin production Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- 108010029697 CD40 Ligand Proteins 0.000 description 4
- 102100032937 CD40 ligand Human genes 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 108060003393 Granulin Proteins 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- 102400000827 Saposin-D Human genes 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229960001561 bleomycin Drugs 0.000 description 4
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000018981 granulocyte chemotaxis Effects 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000005980 lung dysfunction Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 229940097496 nasal spray Drugs 0.000 description 4
- 239000007922 nasal spray Substances 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000006104 solid solution Substances 0.000 description 4
- 230000000365 steroidogenetic effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 229960001423 tetracosactide Drugs 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 229920003134 Eudragit® polymer Polymers 0.000 description 3
- 101000777301 Homo sapiens Uteroglobin Proteins 0.000 description 3
- 206010062767 Hypophysitis Diseases 0.000 description 3
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 3
- 101710200814 Melanotropin alpha Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920012196 Polyoxymethylene Copolymer Polymers 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 206010037423 Pulmonary oedema Diseases 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 229920003086 cellulose ether Polymers 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 206010066336 critical illness polyneuropathy Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 102000056252 human ACE Human genes 0.000 description 3
- 102000055576 human SCGB1A1 Human genes 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 229960003943 hypromellose Drugs 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000011242 neutrophil chemotaxis Effects 0.000 description 3
- 210000003200 peritoneal cavity Anatomy 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 210000003635 pituitary gland Anatomy 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 239000007889 pulsatile dosage form Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 239000007962 solid dispersion Substances 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000037317 transdermal delivery Effects 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010008364 Melanocortins Proteins 0.000 description 2
- 101800000520 Melanotropin gamma Proteins 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 206010053159 Organ failure Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 108010042362 beta-Lipotropin Proteins 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000001601 blood-air barrier Anatomy 0.000 description 2
- 210000005178 buccal mucosa Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 230000002060 circadian Effects 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 229940079360 enema for constipation Drugs 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 230000003352 fibrogenic effect Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003284 homeostatic effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 208000018875 hypoxemia Diseases 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000000813 peptide hormone Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 150000003815 prostacyclins Chemical class 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000003938 response to stress Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000030968 tissue homeostasis Effects 0.000 description 2
- 229940042129 topical gel Drugs 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 210000001631 vena cava inferior Anatomy 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- JMHFFDIMOUKDCZ-NTXHZHDSSA-N 61214-51-5 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 JMHFFDIMOUKDCZ-NTXHZHDSSA-N 0.000 description 1
- RYENLSMHLCNXJT-CYXFISRXSA-N 7-Hydroxymitragynine Chemical compound C1=CC(OC)=C2[C@@]3(O)CCN4C[C@@H](CC)[C@@H](\C(=C/OC)C(=O)OC)C[C@H]4C3=NC2=C1 RYENLSMHLCNXJT-CYXFISRXSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003598 Atelectasis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101800005049 Beta-endorphin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101500024073 Bos taurus Corticotropin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000007809 Boyden Chamber assay Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical group [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010063045 Effusion Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 229920003149 Eudragit® E 100 Polymers 0.000 description 1
- 229920003143 Eudragit® FS 30 D Polymers 0.000 description 1
- 229920003139 Eudragit® L 100 Polymers 0.000 description 1
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 1
- 229920003164 Eudragit® NE 40 D Polymers 0.000 description 1
- 229920003141 Eudragit® S 100 Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- RYENLSMHLCNXJT-UHFFFAOYSA-N Mitragynine hydroxyindolenine Natural products C1=CC(OC)=C2C3(O)CCN4CC(CC)C(C(=COC)C(=O)OC)CC4C3=NC2=C1 RYENLSMHLCNXJT-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 101500024096 Mus musculus Corticotropin Proteins 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- 101500026120 Ovis aries Corticotropin Proteins 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000000683 Pro-Opiomelanocortin Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- 206010051739 Pulmonary sepsis Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101500024108 Rattus norvegicus Corticotropin Proteins 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108010021430 Type 2 Melanocortin Receptor Proteins 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- SPTSIOTYTJZTOG-UHFFFAOYSA-N acetic acid;octadecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O SPTSIOTYTJZTOG-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- UVAZQQHAVMNMHE-XJKSGUPXSA-N alphaprodine Chemical compound C=1C=CC=CC=1[C@@]1(OC(=O)CC)CCN(C)C[C@@H]1C UVAZQQHAVMNMHE-XJKSGUPXSA-N 0.000 description 1
- 229960001349 alphaprodine Drugs 0.000 description 1
- 230000004859 alveolar capillary barrier Effects 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 229960002512 anileridine Drugs 0.000 description 1
- LKYQLAWMNBFNJT-UHFFFAOYSA-N anileridine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC1=CC=C(N)C=C1 LKYQLAWMNBFNJT-UHFFFAOYSA-N 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000007890 bioerodible dosage form Substances 0.000 description 1
- 239000007893 bite-disintegration tablet Substances 0.000 description 1
- 229960004395 bleomycin sulfate Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- PRSUTWWKYIVBEU-HZCBDIJESA-N bromadol Chemical compound C([C@@]1(CC[C@@](CC1)(N(C)C)C=1C=CC(Br)=CC=1)O)CC1=CC=CC=C1 PRSUTWWKYIVBEU-HZCBDIJESA-N 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229950004689 carfentanil Drugs 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003428 dexibuprofen Drugs 0.000 description 1
- HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 description 1
- 229960002783 dexketoprofen Drugs 0.000 description 1
- DKYWVDODHFEZIM-NSHDSACASA-N dexketoprofen Chemical compound OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-NSHDSACASA-N 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- BRTSNYPDACNMIP-FAWZKKEFSA-N dihydroetorphine Chemical compound O([C@H]1[C@@]2(OC)CC[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O BRTSNYPDACNMIP-FAWZKKEFSA-N 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- OEHFRZLKGRKFAS-UHFFFAOYSA-N droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 description 1
- 229960001850 droxicam Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 239000007911 effervescent powder Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 description 1
- 229950004155 etorphine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- FULAPETWGIGNMT-UHFFFAOYSA-N firocoxib Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OCC1CC1 FULAPETWGIGNMT-UHFFFAOYSA-N 0.000 description 1
- 229960002524 firocoxib Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108010075816 gamma-Lipotropin Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000009532 heart rate measurement Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 238000011545 laboratory measurement Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960003406 levorphanol Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229960000994 lumiracoxib Drugs 0.000 description 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002865 melanocortin Substances 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- YDSDEBIZUNNPOB-JVVVGQRLSA-N methyl 1-(2-phenylethyl)-4-(n-propanoylanilino)piperidine-4-carboxylate Chemical compound C1CN(CCC=2C=CC=CC=2)CCC1(C(=O)O[11CH3])N(C(=O)CC)C1=CC=CC=C1 YDSDEBIZUNNPOB-JVVVGQRLSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 239000008185 minitablet Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000144985 peep Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000003863 physical function Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005997 psychological dysfunction Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000007898 rapid-disintegration tablet Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 229940041666 rectal gel Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960005126 tapentadol Drugs 0.000 description 1
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- LZNWYQJJBLGYLT-UHFFFAOYSA-N tenoxicam Chemical compound OC=1C=2SC=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LZNWYQJJBLGYLT-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 239000012443 tonicity enhancing agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/35—Corticotropin [ACTH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Definitions
- Acute respiratory distress syndrome is a type of severe acute lung dysfunction affecting all or most of both lungs and can be a severe complication of any number of factors such as pneumonia, sepsis, trauma, or inhaled irritants. Direct and indirect insults to the parenchyma or vasculature of the lungs are typically followed by rapid-onset respiratory failure. ARDS is a serious condition with associated high mortality that afflicts approximately 200,000 people in the United States each year, leading to approximately 75,000 deaths. A number of clinical trials of treatments for ARDS have been conducted and to date none have been proved highly effective; therefore there is a great need for new, more effective treatments.
- Described herein are methods of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing acute respiratory distress syndrome (ARDS) comprising administration of an adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof.
- the methods described herein can be used to treat an individual diagnosed with ARDS comprising administration of an adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof at a therapeutically effective amount and interval.
- the treatments described herein are prophylactic and used to prevent ARDS.
- the treatments described herein are acute and used to treat ARDS.
- a method of treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof.
- ACTH adrenocorticotropic hormone
- a method of treating an individual diagnosed with or suspected of having, or preventing in an individual at risk for developing, acute respiratory distress syndrome (ARDS) comprising administration of a therapeutically effective amount of an adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof, provided that the adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, does not comprise ⁇ -MSH.
- ARDS acute respiratory distress syndrome
- an adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof for treating an individual diagnosed with, suspected of having, or at risk for developing ARDS.
- ACTH adrenocorticotropic hormone
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered as a first dose and one or more subsequent doses.
- the first dose of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 10 U and about 150 U. In some embodiments, the first dose of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 10 U and about 100 U.
- the first dose of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 10 U and about 150 U, and the one or more subsequent doses of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are between about 20% and about 80% of the first dose. In some embodiments, the first dose of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 10 U and about 150 U, and the one or more subsequent doses of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are between about 20% and about 60% of the first dose.
- the one or more subsequent doses of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof are administered multiple times a day, about every day, about every 2 days, about every 5 days, about every week, about every two weeks, about every three weeks, about every month, about every two months, or any combination thereof.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered as an initial phase of one or more doses and a subsequent phase of one or more doses.
- the initial phase is one, two, three, four, five, six, seven, eight, nine, or ten doses.
- the initial phase is from one to two, one to three, one to four, one to five, one to six, one to seven, one to eight, one to nine, or one to ten doses.
- the dosing intervals of the initial phase and the subsequent are the same. In some embodiments, the dosing intervals of the initial phase and the subsequent are different.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered as an initial phase at daily intervals and a subsequent phase at intervals greater than one day.
- the one or more of the doses of the subsequent phase are administered at intervals of every other day or once every two days, once every three days, once every four days, once every five days, once every six days, once a week, twice a week, three times a week, four times a week, five times a week, six times a week, or once every two weeks, once every three weeks, once every four weeks, once every month, one every two months, or once every three months.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered as an initial phase of from one to five doses at daily intervals and a subsequent phase of one or more doses administered at intervals greater than one day.
- each of the one to five doses of the initial phase is between about 10 U and about 150 U.
- each of the one to five doses of the initial phase is between about 30 U and about 100 U.
- each of the one to five doses of the initial phase is between about 10 U and about 100 U.
- each of the one or more doses of the subsequent phase is between about 30 U and about 100 U.
- each of the one to five doses of the initial phase is about 64 U, and each of the one or more doses of the subsequent phase is about 32 U. In some embodiments, each of the one to five doses of the initial phase is between about 30 U and about 100 U, and each of the one or more doses of the subsequent phase is between about 20% and about 100% of the one to five doses of the initial phase. In some embodiments, each of the one to five doses of the initial phase is between about 10 U and about 150 U, and each of the one or more doses of the subsequent phase is between about 10 U and about 80 U.
- each of the one to five doses of the initial phase is between about 45 U and about 100 U, and each of the one or more doses of the subsequent phase is between about 10 U and about 80 U. In some embodiments, each of the one to five doses of the initial phase is between about 60 U and about 100 U, and each of the one or more doses of the subsequent phase is between about 20 U and about 60 U. In some embodiments, each of the one to five doses of the initial phase is about 80 U, and each of the one or more doses of the subsequent phase is about 40 U.
- the dosing regimen is designed to avoid steroidogenic effects of the ACTH peptide or fragment, analog, complex or aggregate thereof, and lessen the risk of, or avoid, critical illness polymyopathy (CIM) and/or critical illness polyneuropathy (CIP), which are overlapping syndromes of widespread muscle weakness (CIM) and neurological dysfunction (CIP) that can develop as complications in critically ill patients receiving intensive care.
- CCM critical illness polymyopathy
- CIP critical illness polyneuropathy
- CIP critical illness polyneuropathy
- the dose for a patient comprises a first phase of dosing of about 4 to about 10 days duration wherein a patient receives a daily dose of 64 U daily or in a divided dose of 32 U administered at a selected interval within each day, followed by one or more subsequent phases of about 4 to about 10 days duration each wherein each successive phase of doses is about 50% of the dose of the preceding phase, followed by a final phase wherein the dose of the preceding phase in maintained and administered at intervals of every other day.
- the dose for a patient comprises a first phase of dosing of about 7 days duration wherein the dose is administered as 64 U once per day or 32 U twice a day, followed by a second phase of about 7 days duration wherein the daily, or twice daily, dose is reduced by about 50%, followed by a third phase of about 7 days duration wherein the daily, or twice daily, dose of the second phase is reduced by about 50% and followed by a fourth phase of about 7 days, the dose of the third phase is administered every other day.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is an ACTH 1-39 peptide having the formula:
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is an ACTH 1-39 peptide having the formula:
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is an ACTH 1-39 peptide having the formula:
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is an ACTH 1-39 peptide having the formula:
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is an ACTH 1-39 peptide having the formula:
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is an ACTH 1-24 peptide having the formula:
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is an ACTH 1-17 peptide having the formula:
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is a fragment peptide chosen from the group of:
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is a peptide of 17-20 amino acids, 21-25 amino acids, 26-30 amino acids, 31-35 amino acids, 36-40 amino acids, or 40-45 amino acids.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is a peptide with about 50%, 60%, 70%, 80%, 90%, or 100% homology to ACTH. In some embodiments the homologous substitutions are conservative substitutions.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered as an ACTH formulation. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered as ACTHAR® (adrenocorticotropic hormone) gel.
- ACTHAR® adrenocorticotropic hormone
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is formulated as an aerosol, nasal spray, syrup, tablet, mini-tablet, capsule, pill, fast-melt strip, transdermal patch, cream, gel, ointment, solid, liquid solution, emulsion, suspension, powder, injectable solution, intravenous drip, aqueous liquid dispersion, self-emulsifying dispersion, solid solution, liposomal dispersion, immediate release formulation, prodrug, prolonged release formulation, controlled release formulation, fast melt formulation, delayed release formulation, pulsatile release formulation, multiparticulate formulation or mixed immediate and controlled release formulation.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered as a prodrug. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered as a prolonged release formulation. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered as a nasal spray. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is formulated as a gel.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered intramuscularly, subcutaneously, intravenously, intrathecally, orally, systemically, topically, transmucosally, parenterally, intranasally, buccally, or transdermally, rectally, by inhalation or by implant.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered parenterally.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered intramuscularly.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered by injection intramuscularly. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered subcutaneously. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered by injection subcutaneously. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered intravenously. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered intrathecally.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered as an implant. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered via an erodible implant.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is a porcine, human, bovine, sheep, rabbit, chicken, goat or recombinant ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is a porcine ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is a recombinant ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is a recombinant human ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is a synthetic ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, including herein solid phase support sequential synthesis.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is a synthetic human ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is a porcine-derived ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof.
- the methods provided herein further comprise administration of a second therapeutic treatment.
- the second therapeutic treatment is administered sequentially or simultaneously or in staggered sequences.
- the second therapeutic treatment is mechanical ventilation, a glucocorticoid, a surfactant, inhaled nitric oxide, an antioxidant, a protease inhibitor, a recombinant human activated protein C, a ⁇ 2-agonist, lisofylline, a statin, inhaled heparin, a diuretic, a sedative, an analgesic, a muscle relaxant, an antibiotic, inhaled prostacyclin, inhaled synthetic prostacyclin analog, ketoconazole, alprostadil, keratinocyte growth factor, beta-agonists, human monoclonal antibody mAb against TS factor 7a, interferon receptor agonists, insulin, perfluorocarbon, budesonide, recombinant human angiotensin-converting enzyme (ACE), recombinant human Clara cell 10 kDa (CC10) protein, tissue plasminogen activator, human mesenchymal stem cells, nutritional therapy and extra
- the second therapeutic treatment is a glucocorticoid, such as, for example, methylprednisolone, dexamethasone, prednisone, prednisolone, betamethasone, triamcinolone, triamcinolone acetonide, budesonide, and beclometasone; beta-agonists, such as, for example, albuterol; lisofylline; rosuvastatin, inhaled heparin; inhaled nitric oxide; recombinant human activated protein C; NSAIDS, such as, for example, ibuprofen; naproxen, and acetaminophen; cisatracurium besylate; procysteine; acetylcysteine; inhaled prostacyclin; ketoconazole; alprostadil; keratinocyte growth factor; human mAb against TS factor 7a; insulin; perfluorocarbons,
- ARDS is mild to moderate ARDS or moderate to severe ARDS. In certain embodiments, ARDS is mild ARDS. In certain embodiments ARDS is moderate ARDS. In certain embodiments, ARDS is severe ARDS. Clinical measurements of disease severity and rankings made from those measurements are known in the medical literature, some of which are noted herein. There are also known biological markers of disease severity and outcome prognosis that are useful in treating the disease and stratifying patients for treatment. See for example, Johnson, et al. (2010), especially Table 1.
- a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered as a first dose and one or more subsequent doses.
- ACTH adrenocorticotropic hormone
- adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a ACTH 1-39 peptide having the formula:
- adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a ACTH 1-39 peptide having the formula:
- adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a ACTH 1-39 peptide having the formula:
- adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a ACTH 1-39 peptide having the formula:
- adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a ACTH 1-39 peptide having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a ACTH 1-39 peptide having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a ACTH 1-39 peptide having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a ACTH 1-39 peptide having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a ACTH 1-39 peptide having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a ACTH 1-39 peptide having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof as a first and one or more subsequent doses, wherein the first dose of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 10 U and about 150 U, and the one or more subsequent doses of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are between about 20% and about 80% of the first dose.
- the methods described herein comprise administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof as a first and one or more subsequent doses, wherein the first dose of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is about 80 U, and the one or more subsequent doses of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is about 40 U.
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an ACTH 1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an ACTH 1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an ACTH 1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an ACTH 1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an ACTH 1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof.
- ACTH adrenocorticotropic hormone
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered as a first dose and one or more subsequent doses.
- a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered as a first dose and one or more subsequent doses.
- ACTH adrenocorticotropic hormone
- adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof for treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered as a first dose and one or more subsequent doses.
- ACTH adrenocorticotropic hormone
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH is a ACTH 1-39 peptide having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH is a ACTH 1-39 peptide having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH is a ACTH 1-39 peptide having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH is a ACTH 1-39 peptide having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH is a ACTH 1-39 peptide having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH 1-39 peptide, fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH 1-39 peptide, fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH 1-39 peptide, fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH 1-39 peptide, fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH 1-39 peptide, fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof as a first and one or more subsequent doses, wherein the first dose of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 10 U and about 150 U, and the one or more subsequent doses of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof are between about 20% and about 80% of the first dose.
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH 1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH 1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH 1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH 1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH 1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof.
- ACTH adrenocorticotropic hormone
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered as a first dose and one or more subsequent doses.
- a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered as a first dose and one or more subsequent doses.
- ACTH adrenocorticotropic hormone
- adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof for treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered as a first dose and one or more subsequent doses.
- ACTH adrenocorticotropic hormone
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH is a ACTH 1-39 peptide having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH is a ACTH 1-39 peptide having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH is a ACTH 1-39 peptide having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH is a ACTH 1-39 peptide having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH is a ACTH 1-39 peptide having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH 1-39 peptide, fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH 1-39 peptide, fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH 1-39 peptide, fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH 1-39 peptide, fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH 1-39 peptide, fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof as a first and one or more subsequent doses, wherein the first dose of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 10 U and about 150 U, and the one or more subsequent doses of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof are between about 20% and about 80% of the first dose.
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate ARDS comprising administration of an ACTH 1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH 1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH 1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH 1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH 1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
- a method for increasing the safety of administering ACTH 1-39 or ACTH 1-24 or a combination thereof, to a severely ill patient comprising a first phase of dosing of about 4 to about 10 days duration wherein a patient receives a daily dose of 16-64 U daily or in a divided dose of 8-32 U administered at a selected interval within each day, followed by one or more subsequent phases of about 4 to about 10 days duration each wherein each successive phase of doses is about 50% of the dose of the preceding phase, followed by a final phase wherein the dose of the preceding phase in maintained and administered at intervals of every other day.
- a method for increasing the safety of administering ACTH 1-39 or ACTH 1-24 or a combination thereof, to a severely ill patient comprising a first phase of dosing of about 7 days duration wherein the dose is administered as 64 U once per day or 32 U twice a day, followed by a second phase of about 7 days duration wherein the daily, or twice daily, dose is reduced by about 50%, followed by a third phase of about 7 days duration wherein the daily, or twice daily, dose of the second phase is reduced by about 50% and followed by a fourth phase of about 7 days, the dose of the third phase is administered every other day.
- FIG. 1 described in Example 5, illustrates four concentrations of pACTH 1-39 (0.1, 1, 10, 100 ⁇ g/mL) tested in cells isolated from neutrophil donors in response to IL-8.
- FIG. 2 described in Example 6, illustrates the results of granulocyte chemotaxis in vivo by evaluating the effects of ACTHAR® (adrenocorticotropic hormone) on zymosan-induced peritonitis.
- ACTHAR® adrenocorticotropic hormone
- FIG. 3 described in Example 7, illustrates the effects of ACTHAR® (adrenocorticotropic hormone) on IgG production after B cell stimulation with IL4/CD40L.
- ACTHAR® adrenocorticotropic hormone
- FIG. 4 described in Example 8, illustrates the effect of ACTHAR® (adrenocorticotropic hormone) on antibody production associated with antigen-specific immune response.
- FIG. 5 described in Example 9, illustrates the effect of pACTH 1-39 in an in vitro cell model of fibrosis.
- FIG. 6 described in Example 10, illustrates the effect of ACTHAR® (adrenocorticotropic hormone) on the number of animals with no abnormal clinical phenotype after LPS-induced acute lung injury.
- ACTHAR® adrenocorticotropic hormone
- FIG. 7 described in Example 10, illustrates the effect of ACTHAR® (adrenocorticotropic hormone) on edema formation after LPS-induced acute lung injury.
- FIG. 8 described in Example 10, illustrates the effect of ACTHAR® (adrenocorticotropic hormone) on alveolo-capillary permeability following LPS-induced acute lung injury.
- ACTHAR® adrenocorticotropic hormone
- FIG. 9 described in Example 10, illustrates the effect of ACTHAR® (adrenocorticotropic hormone) on airspace inflammation after LPS-induced acute lung injury.
- ACTHAR® adrenocorticotropic hormone
- ARDS acute respiratory distress syndrome
- Experimental and clinical evidence have shown a strong causal relationship between persistence of system inflammation and the progression of ARDS.
- Patients with unresolving ARDS typically have persistent elevation of both systemic and bronchoalveolar lavage levels of inflammatory mediators, fibrogenesis markers, and alveolar-capillary membrane permeability.
- Treatment of ARDS can be directed towards down-regulation of systemic inflammation and restoration of tissue homeostasis.
- ACTH is a hormone that is secreted by the pituitary gland and is a part of the hypothalamus-pituitary-adrenal (HPA) axis that maintains the stress response and homeostasis in the body. As part of the HPA axis, ACTH stimulates the adrenal production of corticosteroids, which are well-acknowledged for their anti-inflammatory effect. Moreover, exogenous corticosteroid therapy can have beneficial effects on the suppression of systemic inflammation, gas exchange, and respiratory mechanics in patients with ARDS [Marik P E, Meduri G U, Rocco P R, Annane D. Glucocorticoid treatment in acute lung injury and acute respiratory distress syndrome. Crit Care Clin.
- HPA hypothalamus-pituitary-adrenal
- ACTH is also an important agonist in the melanocortin system, which has an integral role in homeostatic control of a variety of physiological functions, such as anti-inflammation and immunomodulation.
- ACTH 1-39 binds to and activates all five subtypes of melanocortin receptors with a different affinity and activation at each receptor. [Schiöth H B, Muceniece R, Wikberg J E S, Chhajlani V. Characterisation of melanocortin receptor subtypes by radioligand binding analysis. Eur J Pharmacol. 1995; 288(3):311-7].
- modulation of levels of ACTH can have significant physiological implications.
- the methods of treatment of ARDS described herein comprise administration of adrenocorticotropic hormone (ACTH) to an individual in need thereof in doses and/or dosing regimens such that, for example, any dysregulation in pulmonary function is remedied or partially remedied, thereby alleviating the symptoms of ARDS.
- the methods of treatment of ARDS described herein prevent, delay, reduce, or reverse damage to the lungs, thereby allowing for survival of individuals suspected of having, predisposed to, or at risk for developing ARDS.
- the doses and/or dosing regimens described herein are designed to minimize any abrupt shifts in ACTH levels in an individual (e.g., a surge, or a drop in levels of ACTH) and to moderate the steroidogenic effect on the adrenal medulla.
- ARDS Acute Respiratory Distress Syndrome
- Acute respiratory distress syndrome is a type of severe acute lung dysfunction affecting all or most of both lungs and can be a severe complication of any number of factors such as pneumonia, sepsis, trauma, or inhaled irritants.
- the acute respiratory distress syndrome can be characterized by the influx of protein rich edema fluid into the air spaces due to increased permeability of the alveolar capillary barrier (Ware and Matthay 2000). Accumulation of neutrophils is often predominant in the pulmonary edema fluid and bronchoalveolar-lavage fluid of ARDS patients.
- the protein rich edema fluid in ARDS is typically due to accumulation of neutrophils, monocytes, denuded epithelial cells, and proinflammatory markers such as cytokines, proteases, oxidants, and procoagulant factors (Annual Rev. Pathol. Mech. Dis., 2011, 6, 147-163). Fluid build-up in the lungs leads to impaired gas exchange and occurs with concurrent systemic release of inflammatory mediators, causing inflammation, hypoxemia, and frequently multiple organ failure. Cytokines and other pro-inflammatory compounds can initiate and amplify the inflammatory response in ARDS.
- the acute respiratory distress syndrome if not resolved completely in patients, can progress to fibrosing alveolitis with persistent hypoxemia, increased alveolar dead space, and a further decrease in pulmonary compliance.
- Multiple predisposing disorders as well as secondary factors including alcohol abuse, chronic lung disease, and low serum pH can substantially increase the risk of progression to acute respiratory distress syndrome.
- Complicating factors such as chronic liver disease, nonpulmonary organ dysfunction, sepsis, and advanced age can be used to predict the risk of death at the time of diagnosis of ARDS (Ware and Matthay 2000).
- onset of ARDS is typically within one week of a known clinical insult or new or worsening respiratory symptoms; chest imaging typically include bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules; and the origin of edema typically is not fully explained by cardiac failure or fluid overload and is objectively evaluated (such as by echocardiography) if no clear predisposing factor for ARDS is present.
- the methods of treatment of ARDS described herein are particularly suitable for the treatment of moderate or severe ARDS.
- ARDS afflicts nearly 200,000 people in the United States each year, leading to approximately 75,000 deaths.
- Mechanical ventilation in an intensive care unit is the typical treatment.
- Supportive strategies such as fluid management, sedation interruption, and early mobilization, are typically used as well.
- Patients who survive ARDS have increased risk of lower quality of life, pulmonary-disease specific health related quality of life, persistent cognitive impairment, and physical and psychological dysfunction.
- Examples of residual impairment of pulmonary mechanics and injury to the lung following ARDS include mild restriction, obstruction, impairment of the diffusing capacity of carbon monoxide, or gas exchange abnormalities with exercise.
- ACTH is a 39 amino acid peptide hormone secreted by the anterior pituitary gland. ACTH is secreted from the anterior pituitary in response to corticotropin-releasing hormone (CRH) that is secreted from the hypothalamus. The release of ACTH stimulates melanocortin receptors in the adrenal cortex with subsequent increased production of glucocorticosteroids and/or cortisol from the adrenal cortex, as well as binding to other melanocortin receptor subtypes.
- CSH corticotropin-releasing hormone
- ACTH is synthesized from a precursor polypeptide pre-pro-opiomelanocortin (pre-POMC). The removal of the signal peptide during translation produces a 267 amino acid polypeptide POMC. POMC undergoes a series of post-translational modifications to yield various polypeptide fragments including and not limited to ACTH, ⁇ -lipotropin, ⁇ -lipotropin, ⁇ , ⁇ , ⁇ -Melanocyte Stimulating Hormone (MSH) and ⁇ -endorphin. POMC, ACTH and ⁇ -lipotropin are also secreted from the pituitary gland in response to the hormone corticotropin-releasing hormone (CRH).
- CRCH hormone corticotropin-releasing hormone
- ACTH e.g., ACTH 1-39 or ACTHAR®
- ACTH 1-24 SYNACTHEN®; tetracosactide
- ACTH 1-20 can be advantageous in the methods described herein due to the ability to induce a steroidogenic or a partial steroidogenic effect, depending on the peptide chosen and on the dosage regimen.
- multiple hypothalamic, pituitary, and peripheral factors regulate stress-mediated or inflammation-induced POMC expression and/or ACTH secretion.
- ACTH secretion is characterized by both circadian periodicity and ultradian pulsatility that is generated by CRH release and is also influenced by peripheral corticosteroids.
- ACTH secretion peaks at about before 7 am and nadir adrenal steroid secretion occurs between about 11 pm and 3 am, with periodic secretory bursts occurring throughout the day.
- Serum cortisol levels also exhibit a similar pattern of circadian periodicity. These rhythms are further reinforced by visual cues and the light-dark cycle. In some instances, stress results in increased ACTH pulse amplitude. In some cases stress may be associated with loss of the diurnal rhythms.
- an abnormality in ACTH levels is associated with inflammation (e.g., increased release of pro-inflammatory cytokines).
- an abnormality in ACTH levels is associated with reduced VEGF secretion.
- reduced VEGF secretion is associated with reduced growth of new blood vessels and inadequate oxygen supply to tissues (e.g., neurons and/or muscles).
- ACTH refers to corticotropin, adrenocorticotropic hormone, Tetracosactide or the like.
- the term “ACTH” also includes, but is not limited to, any ACTH peptide or any ACTH preparation as described herein.
- ACTH is an ACTH peptide.
- ACTH peptide refers to ACTH 1-39 peptide of structure:
- ACTH includes peptides or peptide fragments, complexes, salts or aggregates with about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% homology with ACTH 1-39 .
- the term ACTH includes ACTH from any source including human ACTH, mouse ACTH, rat ACTH, porcine ACTH, sheep ACTH, bovine ACTH, rabbit ACTH or any other source of ACTH.
- the ACTH peptide or fragment, analog, complex, or aggregate thereof, or any combination thereof is a porcine ACTH peptide or fragment, analog, complex, or aggregate thereof; a human ACTH peptide or fragment, analog, complex, or aggregate thereof; or a recombinant ACTH peptide or fragment, analog, complex, or aggregate thereof.
- the ACTH peptide is a porcine ACTH peptide, a human ACTH peptide, or a recombinant ACTH peptide.
- the ACTH peptide is a porcine ACTH peptide.
- the ACTH peptide is a human ACTH peptide.
- the ACTH peptide is a recombinant ACTH peptide.
- the ACTH peptide is a recombinant human ACTH peptide.
- ACTH is an ACTH preparation.
- ACTH preparation refers to a mixture containing ACTH peptide and/or other peptide fragments and/or other proteins and/or other substances that together form a composition that is suitable for any methods and/or dosing regimen described herein.
- ACTH is obtained from a homogenized pituitary extract of an appropriate animal (e.g., pituitary extract of a pig). Any suitable method is used to obtain a homogenized pituitary extract.
- a homogenized pituitary extract includes ACTH peptide and/or other peptide fragments and/or other proteins and/or other substances that are contemplated as being part of the ACTH preparation that is compatible with any method described herein.
- ACTH includes humanized and/or recombinant forms of ACTH and synthetic forms of ACTH.
- ACTH includes fragments of ACTH 1-39 .
- Examples of synthetic forms and/or fragments of ACTH include and are not limited to ACTH 1-24 peptide having the formula (e.g., having the sequence of the following) and also known as tetracosactide or SYNACTHEN®:
- ACTH peptide, fragment, or analog does not include a peptide of formula (e.g., having the sequence of the following):
- ACTH also includes synthetic preparations of ACTH that are commercially available including and not limited to ACTHAR® (ADRENOCORTICOTROPIC HORMONE) powder for injection or gel, SYNACTHEN® (tetracosactide), ADRENOMONE® (veterinary adrenocorticotropic hormone compositions), or the like.
- ACTHAR® adrenocorticotropic hormone
- SEQ ID NO: 1 e.g., one or more of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5).
- ACTH peptides examples include and are not limited to Adrenocorticotropic Hormone (ACTH) (1-24) (which is invariant across the mammalian genera), Adrenocorticotropic Hormone (ACTH) (1-39) (human), Adrenocorticotropic Hormone (ACTH) (1-39) (rat), or the like available from, for example, GenScript.
- ACTH 1-24 possesses biological activity equivalent to that of ACTH 1-39 and lesser activity of sequences comprising ACTH 1-19 through ACTH 1-23 is believed to be secondary, not to lessened receptor affinity but to an enhanced rate of in vivo degradation.
- ACTH may also bind the other melanocortin receptors, ie, MC1r, MC3r, MC4r and MC5r, although it is a less potent agonist at these receptors than some of the smaller length melanocortin peptides.
- an ACTH analog refers to any compounds in which one or more atoms, functional groups, or substructures or amino acids, particularly conservative amino acid substitutions, in ACTH or fragments of ACTH have been replaced with different atoms, groups, or substructures or amino acids, or substitution of L-stereoisomers with D-stereoisomers of the amino acids while retaining the functional activity of the ACTH or fragments of ACTH.
- an ACTH analog is a peptide segment of ACTH 1-39 peptide that retains biological activity of ACTH.
- ACTH complex refers to ACTH or fragments or analogs thereof that are optionally complexed with other proteins (e.g., Bovine Serum Albumin) or metal ions, or fragments of ACTH, or any other suitable complexes that retain the functional characteristics of ACTH or ACTH fragments or analogs thereof and/or allow for formulation of ACTH or ACTH fragments or analogs thereof into suitable dosage forms.
- proteins e.g., Bovine Serum Albumin
- prodrug refers to a precursor molecule that is a derivative of ACTH or ACTH fragments or analogs thereof that is suitable for incorporation in any dosage form described herein.
- a “prodrug” refers to a precursor compound that is converted into active compound in vivo.
- Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not.
- the prodrug may also have improved solubility in pharmaceutical compositions over the parent drug.
- prodrugs facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial.
- a prodrug of ACTH or fragment of analog thereof is metabolically stable and is not degraded in the stomach.
- Prodrugs are generally drug precursors that, following administration to a subject and subsequent absorption, are converted to an active, or a more active species via some process, such as conversion by a metabolic pathway. Some prodrugs have a chemical group present on the prodrug that renders it less active and/or less labile and/or confers solubility or some other property to the drug. Once the chemical group has been cleaved and/or modified from the prodrug the active drug is generated.
- a prodrug of ACTH or fragment or analog thereof is an alkyl ester of the parent compound such as, for example, methyl ester, ethyl ester, n-propyl ester, iso-propyl ester, n-butyl ester, sec-butyl ester, tert-butyl ester or any other ester.
- U when appended to dosage amounts, designates a standardized unit of biologic activity as measured by the USP assay for repository corticotropin injection, which provides uniformity of dosing of a hormone peptide, and is expressed as the standardized units of activity per mL, such as, for example, 80 U/mL.
- ARDS adrenocorticotropic hormone
- methods of treatment of ARDS described herein allow for down-regulation of systemic inflammation and/or restoration of tissue homeostasis.
- adrenocorticotropic hormone ACTH
- methods of treatment of lung dysfunction in patients with PaO 2 /FiO 2 ⁇ 100 comprising administration of adrenocorticotropic hormone (ACTH) peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, as described herein, to individuals in need thereof.
- ACTH adrenocorticotropic hormone
- a method of treating an individual diagnosed with or suspected of having, or preventing in an individual at risk for developing, acute respiratory distress syndrome (ARDS) comprising administration of a therapeutically effective amount of an adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof, provided that the adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, does not comprise ⁇ -MSH.
- ARDS acute respiratory distress syndrome
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof may be administered as a first dose, followed by one or more subsequent doses.
- the first dose and one or more subsequent doses of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof are administered in a dosing regimen that is not continuous (e.g., the intervals between doses are uneven).
- the first dose and one or more subsequent doses of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof are administered in a dosing regimen that is a continuous dosing regimen.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof may be administered as a first dose, followed by one or more subsequent doses, wherein the subsequent dose values are equivalent to the initial dose value. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, may be administered as a first dose, followed by one or more subsequent doses, wherein the subsequent dose values are not equivalent to the initial dose value. In some embodiments, the first dose is administered upon detection of one or more symptoms of ARDS in a clinically diagnosed ARDS patient.
- the one or more subsequent doses are administered every day, every other day, every two days, every three days, every four days, every 5 days, every 6 days, once a week, every two weeks, every three weeks, once a month, every six weeks, every two months, every three months, every four months five months, every six months or any combination thereof. In some embodiments, the one or more subsequent doses are administered within the same day, and the dosing is continued as needed.
- the ACTH peptide or fragment, analog, complex or aggregate thereof is administered at onset of ARDS and multiple times a day, every day, about every 2 days, about every 5 days, about every week, about every two weeks, about every three weeks, about every month, about every two months, or any combination thereof as needed.
- the ACTH peptide or fragment, analog, complex or aggregate thereof is administered at one or more intervals during a day, about every day, about every 2 days, about every 5 days, about every week, about every two weeks, about every three weeks, about every month, about every two months, or any combination thereof before onset of ARDS and for as long as the patient experiences ARDS symptoms in the absence of said ACTH peptide or fragment, analog, complex or aggregate thereof.
- the dose comprises a first phase of dosing of about 4 to about 10 days duration wherein a patient receives a daily dose of 64 U daily or in a divided dose of 32 U administered at a selected interval within each day, followed by one or more subsequent phases of about 4 to about 10 days duration each wherein each successive phase of doses is about 50% of the dose of the preceding phase, and a final phase in which the dose of the preceding phase is administered at intervals of every other day.
- the dose comprises a first phase of dosing of about 7 days duration wherein the dose is administered as 64 U once per day or 32 U twice a day, followed by a second phase of about 7 days duration wherein the daily, or twice daily, dose is reduced by about 50%, followed by a third phase of about 7 days duration wherein the daily, or twice daily, dose of the second phase is reduced by about 50% and followed by a fourth phase of about 7 days, wherein the dose of the third phase is administered every other day.
- the dose and frequency of dosing are as set out in Table I.
- the dose and frequency of dosing are as set out in Table II.
- the dosing regimen comprises doses that produce decreasing levels of drug early in the dosing interval followed by a prolonged dose-free interval. In some embodiments, the dosing regimen comprises a first dose, a series of subsequent doses, followed by a drug holiday, and then, one or more series of doses that are the same as or different from the first series of doses.
- the methods of treatment of ARDS described above comprise administration of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, and comprise a first dose of 80 U, then a once daily dose of 20 U for three days, followed by a 40 U dose every week for a month, followed by a period of no treatment for 3 months, and then a second series of doses comprising a first dose of 60 U, then a once daily dose of 20 U for three days, followed by a 40 U dose every week for a month, followed by a period of no treatment for 3 months.
- a dosing regimen comprises dosing that produces escalating levels of drug early in the dosing interval followed by a prolonged dose-free period.
- the methods of treatment of ARDS comprise administration of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, and comprise a first dose of 20 U, a second dose of 20 U in the same week, then 40 U twice a week, then 40 U every other month for three months.
- a first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 10 U, 20 U, 30 U, 40 U, 50 U, 60 U, 70 U, 80 U and about 50 U, 60 U, 70 U, 80 U, 90 U, 100 U, 110 U, 120 U, 130 U, 140 U, 150 U or 200 U.
- a first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 10 U to about 200 U, between about 10 U to about 150 U, between about 10 U to about 100 U, between about 10 U to about 80 U, between about 10 U to about 60 U, or between about 10 U to about 40 U.
- a first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 10 U to about 200 U, between about 20 U to about 200 U, between about 40 U to about 200 U, between about 40 U to about 150 U, between about 40 U to about 100 U, between about 40 U to about 80 U, or between about 40 U to about 60 U.
- a first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 20 U to about 200 U, between about 60 U to about 150 U, between about 60 U to about 100 U, or between about 60 U to about 80 U.
- one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 10 U, 20 U, 30 U, 40 U, 50 U, 60 U, 70 U, 80 U to about 50 U, 60 U, 70 U, 80 U, 90 U, 100 U, 110 U, 120 U, 130 U, 140 U, 150 U or 200 U.
- a one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 10 U to about 200 U, between about 10 U to about 150 U, between about 10 U to about 100 U, between about 10 U to about 80 U, between about 10 U to about 60 U, or between about 10 U to about 40 U.
- a one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 20 U to about 200 U, between about 20 U to about 150 U, between about 20 U to about 100 U, between about 20 U to about 80 U, or between about 20 U to about 60 U, or between about 20 U to about 40 U.
- a one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 40 U to about 200 U, between about 40 U to about 150 U, between about 40 U to about 100 U, between about 40 U to about 80 U, or between about 40 U to about 60 U.
- a one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 20 U to about 200 U, between about 60 U to about 150 U, between about 60 U to about 100 U, or between about 60 U to about 80 U.
- the ACTH, or fragment, analog, complex or aggregate thereof, or any combination thereof is administered as a synthetic preparation (i.e., not naturally occurring), wherein a first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 10 mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg, 50 mg/kg, 60 mg/kg, 70 mg/kg, 80 mg/kg to about 50 mg/kg, 60 mg/kg, 70 mg/kg, 80 mg/kg, 90 mg/kg, 100 mg/kg, 110 mg/kg, 120 mg/kg, 130 mg/kg, 140 mg/kg, 150 mg/kg or 200 mg/kg.
- a first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 10 mg/kg to about 200 mg/kg, between about 20 mg/kg to about 200 mg/kg, between about 20 mg/kg to about 150 mg/kg, between about 20 mg/kg to about 100 mg/kg, between about 20 mg/kg to about 80 mg/kg, between about 20 mg/kg to about 60 mg/kg, or between about 20 mg/kg to about 40 mg/kg.
- a first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 40 mg/kg to about 200 mg/kg, between about 40 mg/kg to about 150 mg/kg, between about 40 mg/kg to about 100 mg/kg, between about 40 mg/kg to about 80 mg/kg, or between about 40 mg/kg to about 60 mg/kg.
- a first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 20 mg/kg to about 200 mg/kg, between about 60 mg/kg to about 150 mg/kg, between about 60 mg/kg to about 100 mg/kg, or between about 60 mg/kg to about 80 mg/kg.
- one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 10 mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg, 50 mg/kg, 60 mg/kg, 70 mg/kg, 80 mg/kg to about 50 mg/kg, 60 mg/kg, 70 mg/kg, 80 mg/kg, 90 mg/kg, 100 mg/kg, 110 mg/kg, 120 mg/kg, 130 mg/kg, 140 mg/kg, 150 mg/kg or 200 mg/kg.
- one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 10 mg/kg to about 200 mg/kg, between about 10 mg/kg to about 150 mg/kg, between about 10 mg/kg to about 100 mg/kg, between about 10 mg/kg to about 80 mg/kg, between about 10 mg/kg to about 60 mg/kg, or between about 10 mg/kg to about 40 mg/kg.
- one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 20 mg/kg to about 200 mg/kg, between about 20 mg/kg to about 150 mg/kg, between about 20 mg/kg to about 100 mg/kg, between about 20 mg/kg to about 80 mg/kg, or between about 20 mg/kg to about 60 mg/kg.
- a one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 40 mg/kg to about 200 mg/kg, between about 40 mg/kg to about 150 mg/kg, between about 40 mg/kg to about 100 mg/kg, between about 40 mg/kg to about 80 mg/kg, or between about 40 mg/kg to about 60 mg/kg.
- a one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 20 mg/kg to about 200 mg/kg, between about 60 mg/kg to about 150 mg/kg, between about 60 mg/kg to about 100 mg/kg, or between about 60 mg/kg to about 80 mg/kg.
- a first dose of ACTH (e.g., synthetically produced ACTH 1-24 ) or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 0.01 mg to about 10 mg, between about 0.1 mg to about 2.5 mg, between about 0.5 mg to about 1 mg, or between about 2 mg to about 5 mg.
- a first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1.0 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3.0 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4.0 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, or about 5 mg.
- one or more subsequent dose of ACTH is between about 0.01 mg to about 10 mg, between about 0.1 mg to about 2.5 mg, between about 0.5 mg to about 1 mg, or between about 2 mg to about 5 mg.
- one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1.0 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3.0 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4.0 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, or about 5 mg.
- one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 10% and about 90%, between about 20% and about 80%, between about 20% and about 60%, or between about 20%—and about 40% of the first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof.
- one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 80% and about 200%, between about 80% and about 175%, between about 80% and about 150%, between about 80% and about 125%, between about 80% and about 100%, between about 100% and 200%, between about 100% and 150%, or between about 100% and 120% of the first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof.
- one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is 100% of the first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered to an individual in need thereof in an amount sufficient to provide plasma cortisol secretion levels between about 1.1 to about 10 times 1.1 to about 8 times, 1.1 to about 6 times, 1.1 to about 4 times, between about 1.1 to about 3 times, between about 1.1 to about 2 times, between about 1.1 to about 1.5 times the plasma cortisol secretion levels of a normal individual at about 8 am.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered to an individual in need thereof in an amount sufficient to provide plasma cortisol secretion levels between about 1.5 to about 4 times, between about 1.5 to about 3 times, or between about 1.15 to about 2 times, the plasma cortisol secretion levels of a normal individual at about 8 am.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered to an individual in need thereof in an amount sufficient to provide plasma cortisol secretion levels between about 1.1 to about 10 times 1.1 to about 8 times, 1.1 to about 6 times, 1.1 to about 4 times, between about 1.1 to about 3 times, between about 1.1 to about 2 times, or between about 1.1 to about 1.5 times the plasma cortisol secretion levels prior to administration of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered to an individual in need thereof in an amount sufficient to provide plasma cortisol secretion levels between about 1.5 to about 4 times, between about 1.5 to about 3 times, or between about 1.15 to about 2 times, the plasma cortisol secretion levels prior to administration of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered in an amount sufficient to provide plasma cortisol concentration between about 1.5 to about 120 ⁇ g/100 mL over at least 24 hours after administration. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered in an amount sufficient to provide plasma cortisol concentration between about 1.5 to about 60 ⁇ g/100 mL over at least 24 hours after administration. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered in an amount sufficient to provide plasma cortisol concentration between about 1.5 to about 30 ⁇ g/100 mL over at least 24 hours after administration.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is optionally administered chronically, that is, for an extended period of time, including throughout the duration of the patient's life in order to ameliorate or otherwise control or limit the symptoms of the patients disease or condition.
- the administration of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is optionally given continuously; alternatively, the dose of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof being administered is temporarily reduced or temporarily suspended for a certain length of time (i.e., a “drug holiday”).
- the length of the drug holiday optionally varies between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, or 365 days.
- the dose reduction during a drug holiday includes from 10%-100%, including, by way of example only, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.
- a maintenance dose is administered if necessary. Subsequently, the dosage or the frequency of administration, or both, is reduced, as a function of the symptoms, to a level at which the improved disease, disorder or condition is retained.
- patients require intermittent treatment on a long-term basis upon any recurrence of symptoms.
- the pharmaceutical compositions described herein are in unit dosage forms suitable for single administration of precise dosages.
- the formulation is divided into unit doses containing appropriate quantities of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof.
- the unit dosage is in the form of a package containing discrete quantities of the formulation.
- Non-limiting examples are packaged tablets or capsules, powders in vials or ampoules, or injectable suspension or solution in ampoules.
- aqueous suspension compositions are packaged in single-dose non-reclosable containers. Alternatively, multiple-dose reclosable containers are used.
- a preservative is optionally included in the composition.
- formulations for intramuscular injection are presented in unit dosage form, which include, but are not limited to ampoules, or in multi dose containers with a rubber septum or similar structure suitable for withdrawing a dose via syringe and with an added preservative.
- Toxicity and therapeutic efficacy of such therapeutic regimens are optionally determined in cell cultures or experimental animals, including, but not limited to, the determination of the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between the toxic and therapeutic effects is the therapeutic index, which is expressed as the ratio between LD50 and ED50.
- ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, exhibiting high therapeutic indices are preferred.
- the data obtained from cell culture assays and animal studies is optionally used in formulating a range of dosage for use in human.
- the dosage of such ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof lies preferably within a range of circulating concentrations that include the ED50 with minimal toxicity.
- the dosage optionally varies within this range depending upon the dosage form employed and the route of administration utilized.
- ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered in combination with other treatments including, and not limited to, ventilation, mechanical ventilation (including newer modes of mechanical ventilation including, but not limited to, high frequency oscillatory ventilation), a glucocorticoid, a surfactant, inhaled nitric oxide, an antioxidant, a protease inhibitor, a recombinant human activated protein C, a ⁇ 2-agonist, lisofylline, a statin, inhaled heparin, a diuretic, a sedative, an analgesic, a muscle relaxant, an antibiotic, inhaled prostacyclin, inhaled synthetic prostacyclin analog, ketoconazole, alprostadil, keratinocyte growth factor, beta-agonists, human mAb against TS factor 7a, interferon receptor agonists, insulin, perfluorocarbon, budesonide
- ventilation including newer modes of mechanical ventilation including, but not limited to
- the other treatment included is a glucocorticoid, such as, for example, methylprednisolone, dexamethasone, prednisone, prednisolone, betamethasone, triamcinolone, triamcinolone acetonide budesonide, and beclometasone; beta-agonists, such as, for example, albuterol; lisofylline; rosuvastatin, inhaled heparin; inhaled nitric oxide; recombinant human activated protein C; NSAIDS, such as, for example, ibuprofen; naproxen, and acetaminophen; cisatracurium besylate; procysteine; acetylcysteine; inhaled prostacyclin; ketoconazole; alprostadil; keratinocyte growth factor; human mAb against TS factor 7a; insulin; perfluorocarbon
- NSAIDS include, but are not limited to, aspirin, acetaminophen, diflunisal, salsalate, ibuprofen, dexibuprofen, naproxen, fenoprofen, ketoprofen, dexketoprofen, flurbiprofen, oxaprozin, loxoprofen, indomethacin, tolmetin, sulindac, etodolac, ketorolac, nabumetone, diclofenac, piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam, isoxicam, metenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid, celecoxib, parecoxib, etoricoxib, lumiracoxib, and firocoxib.
- Analgesics include, but are not limited to, NSAIDS and opioids (narcotics).
- Opioids include, but are not limited to, dextropropoxyphene, codeine, tramadol, tapentadol, anileridine, alphaprodine, pethidine, hydocodone, morphine, oxycodone, methadone, diamorphine, hydromorphone, oxymorphone, levorphanol, 7-hydroxymitragynine, buprenorphine, fentanyl, sufentanil, bromadol, etorphine, dihydroetorphine, and carfentanil.
- Glucocorticoids include, but are not limited to, hydrocortisone, cortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, beclometasone, or fludrocortisones.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, and the second therapeutic treatment are administered simultaneously.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, and the second therapeutic treatment are administered serially in any order.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, and the second therapeutic treatment are administered at different intervals.
- a second therapeutic treatment is administered after completion of a dosing regimen comprising administration of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof.
- compositions comprising at least one ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, where the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is as described herein.
- compositions are formulated using one or more physiologically acceptable carriers including excipients and auxiliaries which facilitate processing of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, into preparations which are used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
- a summary of pharmaceutical compositions is found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Ea hston, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa. 1975; Liberman, H. A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins, 1999).
- compositions that include one or more of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, and a pharmaceutically acceptable diluent(s), excipient(s), or carrier(s).
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is optionally administered as pharmaceutical compositions in which it is mixed with other active ingredients, as in combination therapy.
- the pharmaceutical compositions includes other medicinal or pharmaceutical agents, carriers, adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure, and/or buffers.
- the pharmaceutical compositions also contain other therapeutically valuable substances.
- a pharmaceutical composition refers to a mixture of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients.
- a pharmaceutical composition comprises an ACTH preparation (e.g., an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, and any other proteins and/or other substances that are present in a homogenized pituitary extract obtained from an appropriate animal source) and other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients.
- the pharmaceutical composition facilitates administration of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, to an organism.
- an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof are administered in a pharmaceutical composition to a mammal having a condition, disease, or disorder to be treated.
- the mammal is a human.
- the does and dosing regimen varies depending on the severity and stage of the condition, the age and relative health of an individual, the potency of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, used and other factors.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is optionally used singly or in combination with one or more therapeutic agents as components of mixtures.
- the pharmaceutical formulations described herein are optionally administered to a individual by multiple administration routes, including but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular, intrathecal), intranasal, buccal, topical, rectal, or transdermal administration routes.
- the pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.
- the pharmaceutical compositions will include at least one ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, as an active ingredient in free-acid or free-base form, or in a pharmaceutically acceptable salt form.
- the methods and pharmaceutical compositions described herein include the use of N-oxides, crystalline forms (also known as polymorphs), as well as active metabolites of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the same type of activity.
- ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof exist as tautomers and/or rotational isomers. All tautomers and/or rotational isomers are included within the scope of the embodiments presented herein.
- ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof exists in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.
- the solvated forms of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, presented herein are also considered to be disclosed herein.
- ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof exists as a complex with metal ions, including, for example, Zn +2 ions.
- the metal-ion complexed forms of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, presented herein are also considered to be disclosed herein.
- Carrier materials include any commonly used excipients in pharmaceutics and should be selected on the basis of compatibility with ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, disclosed herein, and the release profile properties of the desired dosage form.
- Exemplary carrier materials include, e.g., binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, diluents, and the like.
- compositions described herein which include a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are formulated into any suitable dosage form, including but not limited to, aqueous oral dispersions, liquids, gels, syrups, elixirs, slurries, suspensions and the like, for oral ingestion by a patient to be treated, solid oral dosage forms, aerosols, controlled release formulations, fast melt formulations, effervescent formulations, lyophilized formulations, tablets, powders, pills, dragees, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate release and controlled release formulations.
- aqueous oral dispersions liquids, gels, syrups, elixirs, slurries, suspensions and the like
- solid oral dosage forms aerosols, controlled release formulations, fast melt formulations, effervescent formulations, lyophilized formulations, tablets, powders,
- a formulation comprising a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is a solid drug dispersion.
- a solid dispersion is a dispersion of one or more active ingredients in an inert carrier or matrix at solid state prepared by the melting (or fusion), solvent, or melting-solvent methods. (Chiou and Riegelman, Journal of Pharmaceutical Sciences, 60, 1281 (1971)). The dispersion of one or more active agents in a solid diluent is achieved without mechanical mixing. Solid dispersions are also called solid-state dispersions.
- any ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, described is formulated as a spray dried dispersion (SDD).
- An SDD is a single phase amorphous molecular dispersion of a drug in a polymer matrix. It is a solid solution prepared by dissolving the drug and a polymer in a solvent (e.g., acetone, methanol or the like) and spray drying the solution. The solvent rapidly evaporates from droplets which rapidly solidifies the polymer and drug mixture trapping the drug in amorphous form as an amorphous molecular dispersion. In some embodiments, such amorphous dispersions are filled in capsules and/or constituted into powders for reconstitution. Solubility of an SDD comprising a drug is higher than the solubility of a crystalline form of a drug or a non-SDD amorphous form of a drug. In some embodiments of the methods described herein, ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are administered as SDDs constituted into appropriate dosage forms described herein.
- a solvent e.g., acetone,
- compositions for oral use are optionally obtained by mixing one or more solid excipient with a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
- Suitable excipients include, for example, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or others such as: polyvinylpyrrolidone (PVP or povidone) or calcium phosphate.
- disintegrating agents are added, such as the cross linked croscarmellose sodium, polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- a prodrug of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is used in preprations for oral use.
- Dragee cores are provided with suitable coatings.
- suitable coatings For this purpose, concentrated sugar solutions are generally used, which optionally contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and % or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments are optionally added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
- the solid dosage forms disclosed herein are in the form of a tablet, (including a suspension tablet, a fast-melt tablet, a bite-disintegration tablet, a rapid-disintegration tablet, an effervescent tablet, or a caplet), a pill, a powder (including a sterile packaged powder, a dispensable powder, or an effervescent powder) a capsule (including both soft or hard capsules, e.g., capsules made from animal-derived gelatin or plant-derived HPMC, or “sprinkle capsules”), solid dispersion, solid solution, bioerodible dosage form, controlled release formulations, pulsatile release dosage forms, multiparticulate dosage forms, pellets, granules, or an aerosol.
- a tablet including a suspension tablet, a fast-melt tablet, a bite-disintegration tablet, a rapid-disintegration tablet, an effervescent tablet, or a caplet
- a pill including a sterile packaged
- the pharmaceutical formulation is in the form of a powder. In still other embodiments, the pharmaceutical formulation is in the form of a tablet, including but not limited to, a fast-melt tablet. Additionally, pharmaceutical formulations of a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are optionally administered as a single capsule or in multiple capsule dosage form. In some embodiments, the pharmaceutical formulation is administered in two, or three, or four, capsules or tablets.
- dosage forms include microencapsulated formulations.
- one or more other compatible materials are present in the microencapsulation material.
- Exemplary materials include, but are not limited to, pH modifiers, erosion facilitators, anti-foaming agents, antioxidants, flavoring agents, and carrier materials such as binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, and diluents.
- Exemplary microencapsulation materials ueful for delaying the release of the formulations including a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof include, but are not limited to, hydroxypropyl cellulose ethers (HPC) such as KLUCEL® (hydroxypropylcellulose) or Nisso HPC, low-substituted hydroxypropyl cellulose ethers (L-HPC), hydroxypropyl methyl cellulose ethers (HPMC) such as Seppifilm-LC, PHARMACOAT® (hypromellose), METOLOSE SR (hypromellose), METHOCEL®-E (cellulose ethers, OPADRY® YS (one step film coating system), PrimaFlo, Benecel MP824, and Benecel MP843, methylcellulose polymers such as METHOCEL®-A (cellulose ethers), hydroxypropylmethylcellulose acetate stearate AQOAT® (HF-LS, HF-LG, HF-
- the pharmaceutical solid oral dosage forms including formulations described herein, which include a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are optionally further formulated to provide a controlled release of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof.
- Controlled release refers to the release of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, from a dosage form in which it is incorporated according to a desired profile over an extended period of time.
- Controlled release profiles include, for example, sustained release, prolonged release, pulsatile release, and delayed release profiles.
- controlled release compositions allow delivery of an agent to a individual over an extended period of time according to a predetermined profile.
- Such release rates provide levels of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, for an extended period of time and thereby provide a longer period of pharmacologic response while minimizing side effects as compared to conventional rapid release dosage forms. Such longer periods of response provide for many inherent benefits that are not achieved with the corresponding short acting, immediate release preparations.
- the formulations described herein, which include a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof are delivered using an implant.
- the implants are formulated to provide a controlled release of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof.
- the implant is an erodible implant.
- the formulations described herein, which include a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof are delivered using a pulsatile dosage form.
- a pulsatile dosage form is capable of providing one or more immediate release pulses at predetermined time points alter a controlled lag time or at specific sites.
- Pulsatile dosage forms including the formulations described herein, which include a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are optionally administered using a variety of pulsatile formulations that include, but are not limited to, those described in U.S. Pat. Nos. 5,011,692, 5,017,381, 5,229,135, and 5,840,329.
- pulsatile release dosage forms suitable for use with the present formulations include, but are not limited to, for example, U.S. Pat. Nos. 4,871,549, 5,260,068, 5,260,069, 5,508,040, 5,567,441 and 5,837,284.
- Liquid formulation dosage forms for oral administration are optionally aqueous suspensions selected from the group including, but not limited to, pharmaceutically acceptable aqueous oral dispersions, emulsions, solutions, elixirs, gels, and syrups. See, e.g., Singh et al., Encyclopedia of Pharmaceutical Technology, 2nd Ed., pp. 754-757 (2002).
- the liquid dosage forms optionally include additives, such as: (a) disintegrating agents; (b) dispersing agents; (c) wetting agents; (d) at least one preservative, (e) viscosity enhancing agents, (f) at least one sweetening agent, and (g) at least one flavoring agent.
- the aqueous dispersions further includes a crystal-forming inhibitor.
- the pharmaceutical formulations described herein are self-emulsifying drug delivery systems (SEDDS).
- SEDDS self-emulsifying drug delivery systems
- Emulsions are dispersions of one immiscible phase in another, usually in the form of droplets.
- emulsions are created by vigorous mechanical dispersion.
- SEDDS as opposed to emulsions or microemulsions, spontaneously form emulsions when added to an excess of water without any external mechanical dispersion or agitation.
- An advantage of SEDDS is that only gentle mixing is required to distribute the droplets throughout the solution. Additionally, water or the aqueous phase is optionally added just prior to administration, which ensures stability of an unstable or hydrophobic active ingredient.
- the SEDDS provides an effective delivery system for oral and parenteral delivery of hydrophobic active ingredients.
- SEDDS provides improvements in the bioavailability of hydrophobic active ingredients.
- Methods of producing self-emulsifying dosage forms include, but are not limited to, for example, U.S. Pat. Nos. 5,858,401, 6,667,048, and 6,960,563.
- Suitable intranasal formulations include those described in, for example, U.S. Pat. Nos. 4,476,116, 5,116,817 and 6,391,452.
- Nasal dosage forms generally contain large amounts of water in addition to the active ingredient. Minor amounts of other ingredients such as pH adjusters, emulsifiers or dispersing agents, preservatives, surfactants, gelling agents, or buffering and other stabilizing and solubilizing agents are optionally present.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is optionally in a form as an aerosol, a mist or a powder.
- Pharmaceutical compositions described herein are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- the dosage unit is determined by providing a valve to deliver a metered amount.
- Capsules and cartridges of, such as, by way of example only, gelatin for use in an inhaler or insufflator are formulated containing a powder mix of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, and a suitable powder base such as lactose or starch.
- buccal formulations that include an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, include, but are not limited to, U.S. Pat. Nos. 4,229,447, 4,596,795, 4,755,386, and 5,739,136.
- the buccal dosage forms described herein optionally further include a bioerodible (hydrolysable) polymeric carrier that also serves to adhere the dosage form to the buccal mucosa.
- the buccal dosage form is fabricated so as to erode gradually over a predetermined time period, wherein the delivery of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is provided essentially throughout.
- the bioerodible (hydrolysable) polymeric carrier generally comprises hydrophilic (water-soluble and water-swellable) polymers that adhere to the wet surface of the buccal mucosa.
- examples of polymeric carriers useful herein include acrylic acid polymers and co, e.g., those known as “carbomers” (CARBOPOL®, which may be obtained from B.F. Goodrich, is one such polymer).
- compositions optionally take the form of tablets, lozenges, or gels formulated in a conventional manner.
- Transdermal formulations of a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are administered for example by those described in U.S. Pat. Nos. 3,598,122, 3,598,123, 3,710,795, 3,731,683, 3,742,951, 3,814,097, 3,921,636, 3,972,995, 3,993,072, 3,993,073, 3,996,934, 4,031,894, 4,060,084, 4,069,307, 4,077,407, 4,201,211, 4,230,105, 4,292,299, 4,292,303, 5,336,168, 5,665,378, 5,837,280, 5,869,090, 6,923,983, 6,929,801 and 6,946,144.
- transdermal formulations described herein include at least three components: (1) a formulation of a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof; (2) a penetration enhancer; and (3) an aqueous adjuvant.
- transdermal formulations include components such as, but not limited to, gelling agents, creams and ointment bases, and the like.
- the transdermal formulation further includes a woven or non-woven backing material to enhance absorption and prevent the removal of the transdermal formulation from the skin.
- the transdermal formulations described herein maintain a saturated or supersaturated state to promote diffusion into the skin.
- formulations suitable for transdermal administration of a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof employ transdermal delivery devices and transdermal delivery patches and are lipophilic emulsions or buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an adhesive. Such patches are optionally constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents. Still further, transdermal delivery of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is optionally accomplished by means of iontophoretic patches and the like. Additionally, transdermal patches provide controlled delivery of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof.
- the rate of absorption is optionally slowed by using rate-controlling membranes or by trapping the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, within a polymer matrix or gel.
- absorption enhancers are used to increase absorption.
- An absorption enhancer or carrier includes absorbable pharmaceutically acceptable solvents to assist passage through the skin.
- transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, optionally with carriers, optionally a rate controlling barrier to deliver the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
- Formulations that include a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, suitable for intramuscular, intrathecal, subcutaneous, or intravenous injection include physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
- aqueous and non-aqueous carriers examples include water, ethanol, polyols (propyleneglycol, polyethylene-glycol, glycerol, cremophor and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
- a coating such as lecithin
- surfactants for subcutaneous injection also contain optional additives such as preserving, wetting, emulsifying, and dispensing agents.
- a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is optionally formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer.
- a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is optionally formulated as a sterile powder for reconstitution into sterile solutions or dispersions for intravenous delivery.
- These ready-made or reconstituted solutions or dispersions for intravenous delivery can be packaged in sterile bags for intravenous drip.
- penetrants appropriate to the barrier to be permeated are used in the formulation.
- appropriate formulations include aqueous or nonaqueous solutions, preferably with physiologically compatible buffers or excipients.
- Parenteral injections optionally involve bolus injection or continuous infusion.
- Formulations for injection are optionally presented in unit dosage form, e.g., in ampoules or in multi dose containers, with an added preservative.
- the pharmaceutical composition described herein are in a form suitable for parenteral injection as a sterile suspensions, solutions or emulsions in oily or aqueous vehicles, and contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- Pharmaceutical formulations for parenteral administration include aqueous solutions of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, in water soluble form, optionally including a gelling agent. Additionally, an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, may be prepared as a lyophilized powder for reconstitution with a physiologically suitable diluent.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered topically and formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams or ointments.
- topically administrable compositions such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams or ointments.
- Such pharmaceutical compositions optionally contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
- the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is also optionally formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas, containing conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, PEG, and the like.
- a low-melting wax such as, but not limited to, a mixture of fatty acid glycerides, optionally in combination with cocoa butter is first melted.
- Circulating NO is measured as an index of systemic inflammation.
- Lung edema is evaluated through histological examination and calculation of the W/D weight ratio.
- the frozen lung samples are used to obtain a gene expression profile to evaluate stress and inflammatory response.
- Three groups of rats receive: intratracheal infusion of endotoxin ( S. typhosa, 500 mg in 0.25 mL saline solution) plus i.p. injections of ACTH (in 0.2 mL solution) at 0, 2, and 4 hours postendotoxin treatment; intratracheal endoxin infusion plus saline injections; control intratracheal saline infusion plus saline injections.
- endotoxin S. typhosa, 500 mg in 0.25 mL saline solution
- ACTH in 0.2 mL solution
- trachea Six hours after endotoxin administration the trachea is cannulated and the cannula is secured with silk thread.
- Cell medium (12 mL) is used to wash the pulmonary tree (injected and withdrawn five times); both the bronchoalveolar lavage (BAL) fluid and whole blood from the jugular vein are transferred to test tubes for analysis in a cell counter.
- BAL bronchoalveolar lavage
- a randomized, double-blind, parallel group, placebo-controlled pilot safety and efficacy study compares three dosing regimens of ACTH to Placebo in patients with moderate or severe ARDS (PaO 2 /FiO 2 ⁇ 200 mmHg with PEEP ⁇ 5 cm H 2 O). A total of ⁇ 130 patients are randomized.
- Patients are eligible for study enrollment if all screening criteria for ARDS are met within the same 24 hour window, and ARDS criteria persist for a minimum of 24 hours and a maximum of 10 days after the initial ARDS diagnosis is made and all inclusion/exclusion criteria are met. Total study duration for each patient including follow-up is approximately 60 days.
- Treatment Period 28 days: At study Day 0, eligible patients undergo baseline assessments, randomization to treatment group, and the first dose of study medication is administered. Safety, tolerability and efficacy of study medication is assessed as long as the patient remains hospitalized. If a patient is discharged from the hospital prior to Day 28, a home visit occurs on Day 28 ( ⁇ 2 days) to conduct required assessments.
- the follow-Up Period begins immediately after the Treatment Period. Patients do not receive study medication during the Follow-Up Period. Day 60 is the last day of study participation for patients, and safety and efficacy assessments are performed.
- the primary outcome measure is the number of ventilator-free days (patient alive and breathing without assistance for ⁇ 48 hours) by Day 28 after randomization.
- the secondary outcome measures include time to successful liberation from ventilator support, defined as ⁇ 48 hours alive and breathing without assistance (supplemental oxygen support is acceptable); number of organ failure-free days during the first 28 and 60 days; number of ICU-free and hospital free days during the first 28 and 60 days for all patients who survive to ICU and hospital discharge, respectively; change over time in PaO2/FiO2 ratio from baseline (Day 0) during the first 28 days; change over time in Lung Injury Score (LIS) from baseline (Day 0) during the first 28 days; change over time in Systemic Organ Failure Assessment Score (SOFA) score during the first 28 days; and mortality at Day 28 and Day 60.
- time to successful liberation from ventilator support defined as ⁇ 48 hours alive and breathing without assistance (supplemental oxygen support is acceptable
- number of organ failure-free days during the first 28 and 60 days number of ICU-free and hospital free days during the first 28 and 60 days for all patients who survive to ICU and hospital discharge, respectively
- change over time in PaO2/FiO2 ratio from baseline (Day 0) during the first
- Safety and tolerability are assessed by treatment-emergent adverse events; physical examinations; laboratory measurements including glycemic status, total daily dose of insulin (TDDI), serum cortisol, hematology, chemistry, and urinalysis; 12-lead electrocardiograms (ECGs); blood pressure (supine) measurement; and heart rate measurement.
- a water-soluble ACTH peptide or fragment, analog, complex or aggregate or salt thereof, or any combination thereof for example, a highly purified sterile preparation of an analog of porcine adrenocorticotropic hormone is admixed with 16% gelatin and then dissolved in sterile, non-pyrogenic water for injection with addition of 0.5% phenol, not more than 0.1% cysteine (added), and sodium hydroxide and/or acetic acid as needed to adjust pH.
- the resulting gel mixture is incorporated into a multi dosage 5 mL vial of a form suitable for administration by injection, the potency of the composition is measured in USP units (designated as “U” which provides a standardized measure of activity) and a multi-dose vial may provide, for example 80 U/mL
- ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is mixed with 50 mg of anhydrous citric acid and 100 mL of 0.9% sodium chloride solution.
- the mixture is incorporated into an inhalation delivery unit, such as a nebulizer, which is suitable for inhalation administration.
- a pharmaceutical composition for rectal delivery 100 mg of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is mixed with 2.5 g of methylcelluose (1500 mPa), 100 mg of methylparapen, 5 g of glycerin and 100 mL of purified water.
- the resulting gel mixture is then incorporated into rectal delivery units, such as syringes, which are suitable for rectal administration.
- a pharmaceutical topical gel composition 100 mg of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is mixed with 1.75 g of hydroxypropyl celluose, 10 mL of propylene glycol, 10 mL of isopropyl myristate and 100 mL of purified alcohol USP. The resulting gel mixture is then incorporated into containers, such as tubes, which are suitable for topicl administration.
- ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, or a prodrug thereof is mixed with 750 mg of starch.
- the mixture is incorporated into an oral dosage unit, such as a hard gelatin capsule, which is suitable for oral administration.
- a pharmaceutical nasal spray solution 10 g of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is mixed with 30 mL of a 0.05M phosphate buffer solution (pH 4.4). The solution is placed in a nasal administrator designed to deliver 100 ⁇ l of spray for each application.
- a 0.05M phosphate buffer solution pH 4.4
- Neutrophils play a role in the pathogenesis of ARDS, and the influx of neutrophils is often observed of patients with ARDS.
- IL-8 (interleukin-8) is a chemotactic factor implicated in the neutrophil recruitment in the lungs of ARDS patients (Clinical Science, 2008, 114, 403-412).
- neutrophil chemotaxis was evaluated using a Boyden chamber assay.
- Four concentrations of pACTH 1-39 (0.1, 1, 10, 100 ⁇ g/mL) were tested in quadruplicate with cells isolated from each neutrophil donor ( FIG. 1 ). Additional studies were performed that confirmed pACTH 1-39 did not exhibit cytotoxicity for human neutrophils. Data were analyzed using GraphPad Prism software and nonparametric analysis (Kruskal Wallis with Dunns multiple comparison post hoc tests). The results demonstrated that pACTH 1-39 attenuated IL-8 induced neutrophil chemotaxis in vitro.
- Granulocyte chemotaxis in vivo was assessed by evaluating the effects of ACTHAR® (adrenocorticotropic hormone) on zymosan-induced peritonitis.
- ACTHAR® adrenocorticotropic hormone
- zymosan heat-killed yeast particles
- Zymosan activates complement, mast cells and peritoneal macrophages, generates proinflammatory mediators, and induces the migration of leukocytes into the peritoneal cavity.
- the infiltrating cells are primarily neutrophils, although monocytes also migrate at later time points.
- mice received dexamethasone (1 mg/kg) or the same volume of vehicle control one hour prior to zymosan injection, as corticosteroid therapy serves as a positive control for efficacy in this model.
- Data were analyzed using GraphPad Prism software and nonparametric analysis (Kruskal Wallis with Dunns multiple comparison post hoc tests). This study demonstrated that ACTHAR® (adrenocorticotropic hormone) attenuated granulocyte chemotaxis in vivo.
- the objective of this study was to evaluate the effects of ACTHAR® (adrenocorticotropic hormone) and placebo gel on antibody production associated with both new and established antigen-specific immune responses.
- Mice were immunized with chicken ovalbumin (Ova) on Day 1 and again on Day 15.
- Treatment with ACTHAR® (adrenocorticotropic hormone) (160 or 400 U/kg) or placebo gel (5 mL/kg) was initiated either on Day 1, prior to immunization, or on Day 15 prior to immunization boost. Circulating serum anti Ova IgG1 levels were measured by ELISA on Day 15 (not shown) and Day 29. Eight animals were studied per group for each treatment and condition.
- porcine ACTH 1-39 supplied by Bachem. Del.
- pACTH 1-39 was tested for its ability to inhibit TGF ⁇ 1-induced differentiation of normal human lung fibroblasts (NHLF) into fibrogenic myofibroblasts producing extracellular matrix (collagen).
- NHLF normal human lung fibroblasts
- FBS medium was changed from 10% FBS to 0.1% FBS
- stimuli and different treatment concentrations were added to the cells
- day 7 the cells were collected and analyzed for matrix protein content.
- the matrix protein content in the culture medium was determined at day 4, and was measured using a Sirius Red based assay (soluble collagen assay kit from QuickZyme). The values were expressed in ⁇ g matrix protein per well (based on a collagen standard). Data were analyzed using GraphPad Prism software and nonparametric analysis (Kruskal Wallis with Dunns multiple comparison post hoc tests). The results demonstrated that pACTH 1-39 attenuated in vitro lung-specific fibrogenic potential ( FIG. 5 ).
- ARDS patients with ARDS typically have increased levels of inflammatory mediators such as IL-6 and IL-8 in lung lining fluid as well as in the circulation.
- High titer of autoantibodies to a number of cytokines have also been detected. These antibodies may be biomarkers for the high levels of cytokines which may cause autoimmunization and possibly contribute to immune dysfunction observed in ARDS (Journal of Translational Medicine, 2010, 8, 97).
- ARDS is associated with high capillary alveolar permeability to proteins (Crit. Care Med., 2001, 29, 10). Different strategies have been developed in order to reproduce the features of human ARDS in animals.
- One such strategy for modeling the disease is to injure the lung directly by a noxious stimulus, including the intratracheal or intranasal administration of bacteria or bacterial products such as LPS, since intra- or extra-pulmonary sepsis is the most common risk factor for the development of ARDS.
- ACTHAR® adrenocorticotropic hormone
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
- This application claims the benefit of U.S. patent application Ser. No. 14/214,449, filed on Mar. 14, 2014, which claims the benefit of U.S. Provisional Patent Application Ser. No. 61/785,631, filed on Mar. 14, 2013, which is herein incorporated by reference in its entirety.
- Acute respiratory distress syndrome (ARDS) is a type of severe acute lung dysfunction affecting all or most of both lungs and can be a severe complication of any number of factors such as pneumonia, sepsis, trauma, or inhaled irritants. Direct and indirect insults to the parenchyma or vasculature of the lungs are typically followed by rapid-onset respiratory failure. ARDS is a serious condition with associated high mortality that afflicts approximately 200,000 people in the United States each year, leading to approximately 75,000 deaths. A number of clinical trials of treatments for ARDS have been conducted and to date none have been proved highly effective; therefore there is a great need for new, more effective treatments.
- Described herein are methods of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing acute respiratory distress syndrome (ARDS) comprising administration of an adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof. In some embodiments, the methods described herein can be used to treat an individual diagnosed with ARDS comprising administration of an adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof at a therapeutically effective amount and interval. In some embodiments, the treatments described herein are prophylactic and used to prevent ARDS. In some embodiments, the treatments described herein are acute and used to treat ARDS.
- In some embodiments, provided herein is a method of treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof.
- In some embodiments, provided herein is a method of treating an individual diagnosed with or suspected of having, or preventing in an individual at risk for developing, acute respiratory distress syndrome (ARDS) comprising administration of a therapeutically effective amount of an adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof, provided that the adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, does not comprise α-MSH.
- In some embodiments, provided herein is the use of an adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof for treating an individual diagnosed with, suspected of having, or at risk for developing ARDS.
- In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered as a first dose and one or more subsequent doses. In some embodiments, the first dose of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 10 U and about 150 U. In some embodiments, the first dose of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 10 U and about 100 U. In some embodiments, the first dose of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 10 U and about 150 U, and the one or more subsequent doses of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are between about 20% and about 80% of the first dose. In some embodiments, the first dose of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 10 U and about 150 U, and the one or more subsequent doses of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are between about 20% and about 60% of the first dose.
- In some embodiments, the one or more subsequent doses of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are administered multiple times a day, about every day, about every 2 days, about every 5 days, about every week, about every two weeks, about every three weeks, about every month, about every two months, or any combination thereof.
- In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered as an initial phase of one or more doses and a subsequent phase of one or more doses. In some cases, the initial phase is one, two, three, four, five, six, seven, eight, nine, or ten doses. In some cases, the initial phase is from one to two, one to three, one to four, one to five, one to six, one to seven, one to eight, one to nine, or one to ten doses. In some embodiments, the dosing intervals of the initial phase and the subsequent are the same. In some embodiments, the dosing intervals of the initial phase and the subsequent are different. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered as an initial phase at daily intervals and a subsequent phase at intervals greater than one day. In some embodiments, the one or more of the doses of the subsequent phase are administered at intervals of every other day or once every two days, once every three days, once every four days, once every five days, once every six days, once a week, twice a week, three times a week, four times a week, five times a week, six times a week, or once every two weeks, once every three weeks, once every four weeks, once every month, one every two months, or once every three months. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered as an initial phase of from one to five doses at daily intervals and a subsequent phase of one or more doses administered at intervals greater than one day. In some embodiments, each of the one to five doses of the initial phase is between about 10 U and about 150 U. In some embodiments, each of the one to five doses of the initial phase is between about 30 U and about 100 U. In some embodiments, each of the one to five doses of the initial phase is between about 10 U and about 100 U. In some embodiments, each of the one or more doses of the subsequent phase is between about 30 U and about 100 U. In some embodiments, each of the one to five doses of the initial phase is about 64 U, and each of the one or more doses of the subsequent phase is about 32 U. In some embodiments, each of the one to five doses of the initial phase is between about 30 U and about 100 U, and each of the one or more doses of the subsequent phase is between about 20% and about 100% of the one to five doses of the initial phase. In some embodiments, each of the one to five doses of the initial phase is between about 10 U and about 150 U, and each of the one or more doses of the subsequent phase is between about 10 U and about 80 U. In some embodiments, each of the one to five doses of the initial phase is between about 45 U and about 100 U, and each of the one or more doses of the subsequent phase is between about 10 U and about 80 U. In some embodiments, each of the one to five doses of the initial phase is between about 60 U and about 100 U, and each of the one or more doses of the subsequent phase is between about 20 U and about 60 U. In some embodiments, each of the one to five doses of the initial phase is about 80 U, and each of the one or more doses of the subsequent phase is about 40 U.
- In some embodiments, the dosing regimen is designed to avoid steroidogenic effects of the ACTH peptide or fragment, analog, complex or aggregate thereof, and lessen the risk of, or avoid, critical illness polymyopathy (CIM) and/or critical illness polyneuropathy (CIP), which are overlapping syndromes of widespread muscle weakness (CIM) and neurological dysfunction (CIP) that can develop as complications in critically ill patients receiving intensive care.
- In one embodiment, the dose for a patient (e.g., an intensive care patient) comprises a first phase of dosing of about 4 to about 10 days duration wherein a patient receives a daily dose of 64 U daily or in a divided dose of 32 U administered at a selected interval within each day, followed by one or more subsequent phases of about 4 to about 10 days duration each wherein each successive phase of doses is about 50% of the dose of the preceding phase, followed by a final phase wherein the dose of the preceding phase in maintained and administered at intervals of every other day.
- In one embodiment, the dose for a patient (e.g., an intensive care patient) comprises a first phase of dosing of about 7 days duration wherein the dose is administered as 64 U once per day or 32 U twice a day, followed by a second phase of about 7 days duration wherein the daily, or twice daily, dose is reduced by about 50%, followed by a third phase of about 7 days duration wherein the daily, or twice daily, dose of the second phase is reduced by about 50% and followed by a fourth phase of about 7 days, the dose of the third phase is administered every other day. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is an ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 1) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Xaa1-Gly-Ala-Glu-Asp-Xaa2- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
or a fragment, complex, aggregate, or analog thereof, or any combination thereof, wherein Xaa1 is Asp or Asn; and Xaa2 is Gln or Glu. - In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is an ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 2) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Gln- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
or a fragment, complex, aggregate, or analog thereof, or any combination thereof. - In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is an ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 3) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
or a fragment, complex, aggregate, or analog thereof, or any combination thereof. - In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is an ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 4) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Glu- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
or a fragment, complex, aggregate, or analog thereof, or any combination thereof. - In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is an ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 5) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Gln- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
or a fragment, complex, aggregate, or analog thereof, or any combination thereof. - In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is an ACTH1-24 peptide having the formula:
-
(SEQ ID NO: 6) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro 21 22 23 24
or a fragment, complex, aggregate, or analog thereof, or any combination thereof. - In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is an ACTH1-17 peptide having the formula:
-
(SEQ ID NO: 7) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg 11 12 13 14 15 16 17
or a fragment, complex, aggregate, or analog thereof, or any combination thereof. - In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a fragment peptide chosen from the group of:
-
(SEQ ID NO: 6) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro 21 22 23 24 and (SEQ ID NO: 7) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg 11 12 13 14 15 16 17
or a complex, aggregate, pharmaceutically acceptable salt, C-terminal ester or amide or N-terminal acetylation thereof, or any combination thereof. - In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is a peptide of 17-20 amino acids, 21-25 amino acids, 26-30 amino acids, 31-35 amino acids, 36-40 amino acids, or 40-45 amino acids.
- In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is a peptide with about 50%, 60%, 70%, 80%, 90%, or 100% homology to ACTH. In some embodiments the homologous substitutions are conservative substitutions.
- In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered as an ACTH formulation. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered as ACTHAR® (adrenocorticotropic hormone) gel. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is formulated as an aerosol, nasal spray, syrup, tablet, mini-tablet, capsule, pill, fast-melt strip, transdermal patch, cream, gel, ointment, solid, liquid solution, emulsion, suspension, powder, injectable solution, intravenous drip, aqueous liquid dispersion, self-emulsifying dispersion, solid solution, liposomal dispersion, immediate release formulation, prodrug, prolonged release formulation, controlled release formulation, fast melt formulation, delayed release formulation, pulsatile release formulation, multiparticulate formulation or mixed immediate and controlled release formulation. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered as a prodrug. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered as a prolonged release formulation. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered as a nasal spray. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is formulated as a gel.
- In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered intramuscularly, subcutaneously, intravenously, intrathecally, orally, systemically, topically, transmucosally, parenterally, intranasally, buccally, or transdermally, rectally, by inhalation or by implant. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered parenterally. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered intramuscularly. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered by injection intramuscularly. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered subcutaneously. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered by injection subcutaneously. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered intravenously. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered intrathecally. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered as an implant. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered via an erodible implant.
- In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a porcine, human, bovine, sheep, rabbit, chicken, goat or recombinant ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a porcine ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a recombinant ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a recombinant human ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a synthetic ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, including herein solid phase support sequential synthesis. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a synthetic human ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a porcine-derived ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof.
- In some embodiments, the methods provided herein further comprise administration of a second therapeutic treatment. In certain embodiments, the second therapeutic treatment is administered sequentially or simultaneously or in staggered sequences.
- In certain embodiments, the second therapeutic treatment is mechanical ventilation, a glucocorticoid, a surfactant, inhaled nitric oxide, an antioxidant, a protease inhibitor, a recombinant human activated protein C, a β2-agonist, lisofylline, a statin, inhaled heparin, a diuretic, a sedative, an analgesic, a muscle relaxant, an antibiotic, inhaled prostacyclin, inhaled synthetic prostacyclin analog, ketoconazole, alprostadil, keratinocyte growth factor, beta-agonists, human monoclonal antibody mAb against TS factor 7a, interferon receptor agonists, insulin, perfluorocarbon, budesonide, recombinant human angiotensin-converting enzyme (ACE), recombinant
human Clara cell 10 kDa (CC10) protein, tissue plasminogen activator, human mesenchymal stem cells, nutritional therapy and extracorporeal membrane oxygenation (ECOM). - In certain embodiments, the second therapeutic treatment is a glucocorticoid, such as, for example, methylprednisolone, dexamethasone, prednisone, prednisolone, betamethasone, triamcinolone, triamcinolone acetonide, budesonide, and beclometasone; beta-agonists, such as, for example, albuterol; lisofylline; rosuvastatin, inhaled heparin; inhaled nitric oxide; recombinant human activated protein C; NSAIDS, such as, for example, ibuprofen; naproxen, and acetaminophen; cisatracurium besylate; procysteine; acetylcysteine; inhaled prostacyclin; ketoconazole; alprostadil; keratinocyte growth factor; human mAb against TS factor 7a; insulin; perfluorocarbons, recombinant human ACE; recombinant human CC10 protein; tissue plasminogen activator; human mesenchymal stem cells; or nutritional therapy such as a combination of omega-3 fatty acids, antioxidants, and γ-linolenic acids with isocaloric foods and extracorporeal membrane oxygenation (ECMO).
- In some embodiments, ARDS is mild to moderate ARDS or moderate to severe ARDS. In certain embodiments, ARDS is mild ARDS. In certain embodiments ARDS is moderate ARDS. In certain embodiments, ARDS is severe ARDS. Clinical measurements of disease severity and rankings made from those measurements are known in the medical literature, some of which are noted herein. There are also known biological markers of disease severity and outcome prognosis that are useful in treating the disease and stratifying patients for treatment. See for example, Johnson, et al. (2010), especially Table 1.
- In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered as a first dose and one or more subsequent doses.
- In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with or suspected of having, or at risk of developing ARDS comprising administration of adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 1) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arq-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Xaa1-Gly-Ala-Glu-Asp-Xaa2- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
or a fragment, complex, aggregate, or analog thereof, or any combination thereof, wherein Xaa1 is Asp or Asn; and Xaa2 is Gln or Glu. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 2) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Gln- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
or a fragment, complex, aggregate, or analog thereof, or any combination thereof. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 3) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Aro-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
or a fragment, complex, aggregate, or analog thereof, or any combination thereof. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 4) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Glu- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
or a fragment, complex, aggregate, or analog thereof, or any combination thereof. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 5) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Gln- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
or a fragment, complex, aggregate, or analog thereof, or any combination thereof. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 1) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Xaa1-Gly-Ala-Glu-Asp-Xaa2- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first dose and one or more subsequent doses, wherein Xaa1 is Asp or Asn; and Xaa2 is Gln or Glu. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 2) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Gln- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first dose and one or more subsequent doses. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 3) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first dose and one or more subsequent doses. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 4) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Glu- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first dose and one or more subsequent doses. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 5) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Aro-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Gln- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first dose and one or more subsequent doses. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof as a first and one or more subsequent doses, wherein the first dose of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 10 U and about 150 U, and the one or more subsequent doses of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are between about 20% and about 80% of the first dose. In further embodiments, the methods described herein comprise administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof as a first and one or more subsequent doses, wherein the first dose of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is about 80 U, and the one or more subsequent doses of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is about 40 U.
- In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an ACTH1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 1) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Aro-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Xaa1-Gly-Ala-Glu-Asp-Xaa2- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
wherein Xaa1 is Asp or Asn; and Xaa2 is Gln or Glu, as a first and one or more subsequent doses, wherein the first dose is between about 10 U and about 150 U, and the one or more subsequent doses are between about 20% and about 80% of the first dose. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an ACTH1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 2) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Gln- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first and one or more subsequent doses, wherein the first dose is between about 10 U and about 150 U, and the one or more subsequent doses are between about 20% and about 80% of the first dose. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an ACTH1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 3) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first and one or more subsequent doses, wherein the first dose is between about 10 U and about 150 U, and the one or more subsequent doses are between about 20% and about 80% of the first dose. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an ACTH1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 4) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Glu- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first and one or more subsequent doses, wherein the first dose is between about 10 U and about 150 U, and the one or more subsequent doses are between about 20% and about 80% of the first dose. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing ARDS comprising administration of an ACTH1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 5) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Gln- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first and one or more subsequent doses, wherein the first dose is between about 10 U and about 150 U, and the one or more subsequent doses are between about 20% and about 80% of the first dose. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof.
- In certain embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered as a first dose and one or more subsequent doses.
- In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered as a first dose and one or more subsequent doses.
- In some embodiments, provided herein is the use of adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof for treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered as a first dose and one or more subsequent doses.
- In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH is a ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 1) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Xaa1-Gly-Ala-Glu-Asp-Xaa2- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
or a fragment, complex, aggregate, or analog thereof, or any combination thereof, wherein Xaa1 is Asp or Asn; and Xaa2 is Gln or Glu. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH is a ACTH1-39 peptide having the formula:
-
(SEO ID NO: 2) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Gln- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
or a fragment, complex, aggregate, or analog thereof, or any combination thereof. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH is a ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 3) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
or a fragment, complex, aggregate, or analog thereof, or any combination thereof. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH is a ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 4) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Glu- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
or a fragment, complex, aggregate, or analog thereof, or any combination thereof. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH is a ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 5) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Gln- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
or a fragment, complex, aggregate, or analog thereof, or any combination thereof. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH1-39 peptide, fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 1) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Xaa1-Gly-Ala-Glu-Asp-Xaa2- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first dose and one or more subsequent doses, wherein Xaa1 is Asp or Asn; and Xaa2 is Gln or Glu. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH1-39 peptide, fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 2) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Gln- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first dose and one or more subsequent doses. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH1-39 peptide, fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 3) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first dose and one or more subsequent doses. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH1-39 peptide, fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 4) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Glu- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first dose and one or more subsequent doses. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH1-39 peptide, fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 5) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Gln- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first dose and one or more subsequent doses. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof as a first and one or more subsequent doses, wherein the first dose of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 10 U and about 150 U, and the one or more subsequent doses of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof are between about 20% and about 80% of the first dose.
- In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 1) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arq-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Xaa1-Gly-Ala-Glu-Asp-Xaa2- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
wherein Xaa1 is Asp or Asn; and Xaa2 is Gln or Glu, as a first and one or more subsequent doses, wherein the first dose is between about 10 U and about 150 U, and the one or more subsequent doses are between about 20% and about 80% of the first dose. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 2) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Gln- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-GLu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first and one or more subsequent doses, wherein the first dose is between about 10 U and about 150 U, and the one or more subsequent doses are between about 20% and about 80% of the first dose. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 3) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first and one or more subsequent doses, wherein the first dose is between about 10 U and about 150 U, and the one or more subsequent doses are between about 20% and about 80% of the first dose. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 4) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Glu- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first and one or more subsequent doses, wherein the first dose is between about 10 U and about 150 U, and the one or more subsequent doses are between about 20% and about 80% of the first dose. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate to severe ARDS comprising administration of an ACTH1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 5) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Gln- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first and one or more subsequent doses, wherein the first dose is between about 10 U and about 150 U, and the one or more subsequent doses are between about 20% and about 80% of the first dose. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof.
- In certain embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered as a first dose and one or more subsequent doses.
- In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is administered as a first dose and one or more subsequent doses.
- In some embodiments, provided herein is the use of adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof for treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered as a first dose and one or more subsequent doses.
- In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH is a ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 1) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Xaa1-Gly-Ala-Glu-Asp-Xaa2- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
or a fragment, complex, aggregate, or analog thereof, or any combination thereof, wherein Xaa1 is Asp or Asn; and Xaa2 is Gln or Glu. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH is a ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 5) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Gln- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
or a fragment, complex, aggregate, or analog thereof, or any combination thereof. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH is a ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 3) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
or a fragment, complex, aggregate, or analog thereof, or any combination thereof. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH is a ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 4) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Glu- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
or a fragment, complex, aggregate, or analog thereof, or any combination thereof. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, wherein the ACTH is a ACTH1-39 peptide having the formula:
-
(SEQ ID NO: 2) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Gln- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
or a fragment, complex, aggregate, or analog thereof, or any combination thereof. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH1-39 peptide, fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 1) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Xaa1-Gly-Ala-Glu-Asp-Xaa2- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
As a first dose and one or more subsequent doses, wherein Xaa1 is Asp or Asn; and Xaa2 is Gln or Glu. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH1-39 peptide, fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 2) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Gln- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first dose and one or more subsequent doses. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH1-39 peptide, fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 3) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first dose and one or more subsequent doses. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH1-39 peptide, fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 4) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Glu- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first dose and one or more subsequent doses. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH1-39 peptide, fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 5) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Gln- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first dose and one or more subsequent doses. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof as a first and one or more subsequent doses, wherein the first dose of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is between about 10 U and about 150 U, and the one or more subsequent doses of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof are between about 20% and about 80% of the first dose.
- In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing moderate ARDS comprising administration of an ACTH1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 1) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Xaa1-Gly-Ala-Glu-Asp-Xaa2- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first and one or more subsequent doses, wherein the first dose is between about 10 U and about 150 U, and the one or more subsequent doses are between about 20% and about 80% of the first dose, and wherein Xaa1 is Asp or Asn; and Xaa2 is Gln or Glu. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 2) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 6 17 18 19 20 Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Gln- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first and one or more subsequent doses, wherein the first dose is between about 10 U and about 150 U, and the one or more subsequent doses are between about 20% and about 80% of the first dose. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 3) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first and one or more subsequent doses, wherein the first dose is between about 10 U and about 150 U, and the one or more subsequent doses are between about 20% and about 80% of the first dose. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 4) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Glu- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first and one or more subsequent doses, wherein the first dose is between about 10 U and about 150 U, and the one or more subsequent doses are between about 20% and about 80% of the first dose. - In some embodiments, provided herein is a method of preventing or treating an individual diagnosed with, suspected of having, or at risk for developing mild to moderate ARDS comprising administration of an ACTH1-39 peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the formula:
-
(SEQ ID NO: 5) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Gln- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
as a first and one or more subsequent doses, wherein the first dose is between about 10 U and about 150 U, and the one or more subsequent doses are between about 20% and about 80% of the first dose. - In some embodiments, provided herein is a method for increasing the safety of administering ACTH1-39 or ACTH1-24 or a combination thereof, to a severely ill patient comprising a first phase of dosing of about 4 to about 10 days duration wherein a patient receives a daily dose of 16-64 U daily or in a divided dose of 8-32 U administered at a selected interval within each day, followed by one or more subsequent phases of about 4 to about 10 days duration each wherein each successive phase of doses is about 50% of the dose of the preceding phase, followed by a final phase wherein the dose of the preceding phase in maintained and administered at intervals of every other day.
- In some embodiments, provided herein is a method for increasing the safety of administering ACTH1-39 or ACTH1-24 or a combination thereof, to a severely ill patient comprising a first phase of dosing of about 7 days duration wherein the dose is administered as 64 U once per day or 32 U twice a day, followed by a second phase of about 7 days duration wherein the daily, or twice daily, dose is reduced by about 50%, followed by a third phase of about 7 days duration wherein the daily, or twice daily, dose of the second phase is reduced by about 50% and followed by a fourth phase of about 7 days, the dose of the third phase is administered every other day.
- All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
- The novel features of the invention are set forth with particularity in the appended claims. The invention is better understood from the following detailed description when read in conjunction with the accompanying drawings. It is emphasized that according to common practice, the various features of the drawings are not to-scale. On the contrary, the dimensions of the various features are arbitrarily expanded or reduced for clarity. Included in the drawings are the following figures.
-
FIG. 1 , described in Example 5, illustrates four concentrations of pACTH1-39 (0.1, 1, 10, 100 μg/mL) tested in cells isolated from neutrophil donors in response to IL-8. -
FIG. 2 , described in Example 6, illustrates the results of granulocyte chemotaxis in vivo by evaluating the effects of ACTHAR® (adrenocorticotropic hormone) on zymosan-induced peritonitis. -
FIG. 3 , described in Example 7, illustrates the effects of ACTHAR® (adrenocorticotropic hormone) on IgG production after B cell stimulation with IL4/CD40L. -
FIG. 4 , described in Example 8, illustrates the effect of ACTHAR® (adrenocorticotropic hormone) on antibody production associated with antigen-specific immune response. -
FIG. 5 , described in Example 9, illustrates the effect of pACTH1-39 in an in vitro cell model of fibrosis. -
FIG. 6 , described in Example 10, illustrates the effect of ACTHAR® (adrenocorticotropic hormone) on the number of animals with no abnormal clinical phenotype after LPS-induced acute lung injury. -
FIG. 7 , described in Example 10, illustrates the effect of ACTHAR® (adrenocorticotropic hormone) on edema formation after LPS-induced acute lung injury. -
FIG. 8 , described in Example 10, illustrates the effect of ACTHAR® (adrenocorticotropic hormone) on alveolo-capillary permeability following LPS-induced acute lung injury. -
FIG. 9 , described in Example 10, illustrates the effect of ACTHAR® (adrenocorticotropic hormone) on airspace inflammation after LPS-induced acute lung injury. - Provided herein, in some embodiments, are methods of treatment of acute respiratory distress syndrome (ARDS) comprising administration of ACTH to an individual in need thereof. Experimental and clinical evidence have shown a strong causal relationship between persistence of system inflammation and the progression of ARDS. Patients with unresolving ARDS typically have persistent elevation of both systemic and bronchoalveolar lavage levels of inflammatory mediators, fibrogenesis markers, and alveolar-capillary membrane permeability. Treatment of ARDS can be directed towards down-regulation of systemic inflammation and restoration of tissue homeostasis.
- ACTH is a hormone that is secreted by the pituitary gland and is a part of the hypothalamus-pituitary-adrenal (HPA) axis that maintains the stress response and homeostasis in the body. As part of the HPA axis, ACTH stimulates the adrenal production of corticosteroids, which are well-acknowledged for their anti-inflammatory effect. Moreover, exogenous corticosteroid therapy can have beneficial effects on the suppression of systemic inflammation, gas exchange, and respiratory mechanics in patients with ARDS [Marik P E, Meduri G U, Rocco P R, Annane D. Glucocorticoid treatment in acute lung injury and acute respiratory distress syndrome. Crit Care Clin. 2011; 27(3):589-607; Meduri G U, Headley A S, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: A randomized controlled trial. JAMA. 1998; 280(2):159-165]. ACTH is also an important agonist in the melanocortin system, which has an integral role in homeostatic control of a variety of physiological functions, such as anti-inflammation and immunomodulation. ACTH1-39 binds to and activates all five subtypes of melanocortin receptors with a different affinity and activation at each receptor. [Schiöth H B, Muceniece R, Wikberg J E S, Chhajlani V. Characterisation of melanocortin receptor subtypes by radioligand binding analysis. Eur J Pharmacol. 1995; 288(3):311-7]. Thus, modulation of levels of ACTH can have significant physiological implications.
- Advantageously, in some embodiments, the methods of treatment of ARDS described herein comprise administration of adrenocorticotropic hormone (ACTH) to an individual in need thereof in doses and/or dosing regimens such that, for example, any dysregulation in pulmonary function is remedied or partially remedied, thereby alleviating the symptoms of ARDS. In some embodiments, the methods of treatment of ARDS described herein prevent, delay, reduce, or reverse damage to the lungs, thereby allowing for survival of individuals suspected of having, predisposed to, or at risk for developing ARDS. In certain embodiments, the doses and/or dosing regimens described herein are designed to minimize any abrupt shifts in ACTH levels in an individual (e.g., a surge, or a drop in levels of ACTH) and to moderate the steroidogenic effect on the adrenal medulla.
- Acute respiratory distress syndrome, or adult respiratory distress syndrome, is a type of severe acute lung dysfunction affecting all or most of both lungs and can be a severe complication of any number of factors such as pneumonia, sepsis, trauma, or inhaled irritants. The acute respiratory distress syndrome can be characterized by the influx of protein rich edema fluid into the air spaces due to increased permeability of the alveolar capillary barrier (Ware and Matthay 2000). Accumulation of neutrophils is often predominant in the pulmonary edema fluid and bronchoalveolar-lavage fluid of ARDS patients. The protein rich edema fluid in ARDS is typically due to accumulation of neutrophils, monocytes, denuded epithelial cells, and proinflammatory markers such as cytokines, proteases, oxidants, and procoagulant factors (Annual Rev. Pathol. Mech. Dis., 2011, 6, 147-163). Fluid build-up in the lungs leads to impaired gas exchange and occurs with concurrent systemic release of inflammatory mediators, causing inflammation, hypoxemia, and frequently multiple organ failure. Cytokines and other pro-inflammatory compounds can initiate and amplify the inflammatory response in ARDS. The acute respiratory distress syndrome, if not resolved completely in patients, can progress to fibrosing alveolitis with persistent hypoxemia, increased alveolar dead space, and a further decrease in pulmonary compliance. Multiple predisposing disorders as well as secondary factors including alcohol abuse, chronic lung disease, and low serum pH can substantially increase the risk of progression to acute respiratory distress syndrome. Complicating factors such as chronic liver disease, nonpulmonary organ dysfunction, sepsis, and advanced age can be used to predict the risk of death at the time of diagnosis of ARDS (Ware and Matthay 2000).
- The Berlin Definition of ARDS partitions patients of ARDS by arterial partial pressure of oxygen to fraction of inspired oxygen ratio (PaO2/FiO2) into three levels of the syndrome: mild ARDS (PaO2/FiO2′ 200-300), moderate ARDS (PaO2/FiO2=100-199), and severe ARDS (PaO2/FiO2<100). In addition, onset of ARDS is typically within one week of a known clinical insult or new or worsening respiratory symptoms; chest imaging typically include bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules; and the origin of edema typically is not fully explained by cardiac failure or fluid overload and is objectively evaluated (such as by echocardiography) if no clear predisposing factor for ARDS is present. In some embodiments, the methods of treatment of ARDS described herein are particularly suitable for the treatment of moderate or severe ARDS.
- ARDS afflicts nearly 200,000 people in the United States each year, leading to approximately 75,000 deaths. Mechanical ventilation in an intensive care unit is the typical treatment. Supportive strategies, such as fluid management, sedation interruption, and early mobilization, are typically used as well. Patients who survive ARDS have increased risk of lower quality of life, pulmonary-disease specific health related quality of life, persistent cognitive impairment, and physical and psychological dysfunction. Examples of residual impairment of pulmonary mechanics and injury to the lung following ARDS include mild restriction, obstruction, impairment of the diffusing capacity of carbon monoxide, or gas exchange abnormalities with exercise.
- ACTH is a 39 amino acid peptide hormone secreted by the anterior pituitary gland. ACTH is secreted from the anterior pituitary in response to corticotropin-releasing hormone (CRH) that is secreted from the hypothalamus. The release of ACTH stimulates melanocortin receptors in the adrenal cortex with subsequent increased production of glucocorticosteroids and/or cortisol from the adrenal cortex, as well as binding to other melanocortin receptor subtypes.
- ACTH is synthesized from a precursor polypeptide pre-pro-opiomelanocortin (pre-POMC). The removal of the signal peptide during translation produces a 267 amino acid polypeptide POMC. POMC undergoes a series of post-translational modifications to yield various polypeptide fragments including and not limited to ACTH, β-lipotropin, γ-lipotropin, α, β, γ-Melanocyte Stimulating Hormone (MSH) and β-endorphin. POMC, ACTH and β-lipotropin are also secreted from the pituitary gland in response to the hormone corticotropin-releasing hormone (CRH). Without being bound to any one particular theory, it is believed that ACTH (e.g., ACTH1-39 or ACTHAR®) or fragments thereof, such as for example, ACTH1-24 (SYNACTHEN®; tetracosactide) or ACTH1-20, can be advantageous in the methods described herein due to the ability to induce a steroidogenic or a partial steroidogenic effect, depending on the peptide chosen and on the dosage regimen. In some embodiments, multiple hypothalamic, pituitary, and peripheral factors regulate stress-mediated or inflammation-induced POMC expression and/or ACTH secretion. Essential cellular functions maintaining metabolic and neuroendocrine control require a homeostatic, non-stressed pattern of ACTH and glucocorticoid secretion. ACTH secretion is characterized by both circadian periodicity and ultradian pulsatility that is generated by CRH release and is also influenced by peripheral corticosteroids. Thus, ACTH secretion peaks at about before 7 am and nadir adrenal steroid secretion occurs between about 11 pm and 3 am, with periodic secretory bursts occurring throughout the day. Serum cortisol levels also exhibit a similar pattern of circadian periodicity. These rhythms are further reinforced by visual cues and the light-dark cycle. In some instances, stress results in increased ACTH pulse amplitude. In some cases stress may be associated with loss of the diurnal rhythms.
- In some instances, an abnormality in ACTH levels is associated with inflammation (e.g., increased release of pro-inflammatory cytokines). In some instances, an abnormality in ACTH levels is associated with reduced VEGF secretion. In some instances, reduced VEGF secretion is associated with reduced growth of new blood vessels and inadequate oxygen supply to tissues (e.g., neurons and/or muscles).
- For the purpose of interpreting this specification, the following definitions will apply. In the event that any definition set forth below conflicts with the usage of that word in any other document, including any document incorporated herein by reference, the definition set forth below shall always control for purposes of interpreting this specification and its associated claims unless a contrary meaning is clearly intended (for example by reference to a document where the term is originally used). Whenever appropriate, terms used in the singular also will include the plural and vice versa. The use of “a” herein means “one or more” unless stated otherwise or where the use of “one or more” is clearly inappropriate. The use of “or” means “and/or” unless stated otherwise. The use of “comprise,” “comprises,” “comprising,” “include,” “includes,” and “including” are interchangeable and not intended to be limiting. The term “such as” also is not intended to be limiting. For example, the term “including” shall mean “including, but not limited to.”
- The term “ACTH” refers to corticotropin, adrenocorticotropic hormone, Tetracosactide or the like. The term “ACTH” also includes, but is not limited to, any ACTH peptide or any ACTH preparation as described herein. In some embodiments, ACTH is an ACTH peptide. As used herein, in some embodiments, “ACTH peptide” refers to ACTH1-39 peptide of structure:
-
(SEQ ID NO: 1) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro-Xaa1-Gly-Ala-Glu-Asp-Xaa2- 21 22 23 24 25 26 27 28 29 30 Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 31 32 33 34 35 36 37 38 39
or any homologs, analogs, fragments, complexes or aggregates thereof, wherein Xaa1 is Asp or Asn; and Xaa2 is Gln or Glu. The term ACTH includes peptides or peptide fragments, complexes, salts or aggregates with about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% homology with ACTH1-39. The term ACTH includes ACTH from any source including human ACTH, mouse ACTH, rat ACTH, porcine ACTH, sheep ACTH, bovine ACTH, rabbit ACTH or any other source of ACTH. - In some embodiments, the ACTH peptide or fragment, analog, complex, or aggregate thereof, or any combination thereof, is a porcine ACTH peptide or fragment, analog, complex, or aggregate thereof; a human ACTH peptide or fragment, analog, complex, or aggregate thereof; or a recombinant ACTH peptide or fragment, analog, complex, or aggregate thereof. In some embodiments, the ACTH peptide is a porcine ACTH peptide, a human ACTH peptide, or a recombinant ACTH peptide. In some embodiments, the ACTH peptide is a porcine ACTH peptide. In some embodiments, the ACTH peptide is a human ACTH peptide. In some embodiments, the ACTH peptide is a recombinant ACTH peptide. In some embodiments, the ACTH peptide is a recombinant human ACTH peptide.
- In some embodiments, ACTH is an ACTH preparation. As used herein, “ACTH preparation” refers to a mixture containing ACTH peptide and/or other peptide fragments and/or other proteins and/or other substances that together form a composition that is suitable for any methods and/or dosing regimen described herein. In some of such embodiments, ACTH is obtained from a homogenized pituitary extract of an appropriate animal (e.g., pituitary extract of a pig). Any suitable method is used to obtain a homogenized pituitary extract. In some of such embodiments, a homogenized pituitary extract includes ACTH peptide and/or other peptide fragments and/or other proteins and/or other substances that are contemplated as being part of the ACTH preparation that is compatible with any method described herein.
- The term ACTH includes humanized and/or recombinant forms of ACTH and synthetic forms of ACTH. The term ACTH includes fragments of ACTH1-39. Examples of synthetic forms and/or fragments of ACTH include and are not limited to ACTH1-24 peptide having the formula (e.g., having the sequence of the following) and also known as tetracosactide or SYNACTHEN®:
-
(SEQ ID NO: 6) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly- 1 2 3 4 5 6 7 8 9 10 Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val- 11 12 13 14 15 16 17 18 19 20 Lys-Val-Tyr-Pro 21 22 23 24 - The term ACTH peptide, fragment, or analog does not include a peptide of formula (e.g., having the sequence of the following):
- Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 NO: 8) which is known as alpha-MSH or an analog thereof, or a peptide fragment of formula (e.g., having the sequence of the following):
-
(SEQ ID NO: 9) H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro- Val
or an analog thereof, or any combination thereof. - The term ACTH also includes synthetic preparations of ACTH that are commercially available including and not limited to ACTHAR® (ADRENOCORTICOTROPIC HORMONE) powder for injection or gel, SYNACTHEN® (tetracosactide), ADRENOMONE® (veterinary adrenocorticotropic hormone compositions), or the like. ACTHAR® (adrenocorticotropic hormone) is derived from porcine pituitary glands and the ACTH obtained therefrom includes one or more of the ACTH peptides of SEQ ID NO: 1 (e.g., one or more of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5). Examples of commercially available ACTH peptides that are compatible with the methods described herein include and are not limited to Adrenocorticotropic Hormone (ACTH) (1-24) (which is invariant across the mammalian genera), Adrenocorticotropic Hormone (ACTH) (1-39) (human), Adrenocorticotropic Hormone (ACTH) (1-39) (rat), or the like available from, for example, GenScript. ACTH1-24 possesses biological activity equivalent to that of ACTH1-39 and lesser activity of sequences comprising ACTH1-19 through ACTH1-23 is believed to be secondary, not to lessened receptor affinity but to an enhanced rate of in vivo degradation. Peptide sequences smaller than 1-18 exhibit markedly diminished activity at the MC2 receptor (Krieger 1982) in comparison to ACTH1-24 and higher. The C-terminal 25-39 appears to influence the degradation of the molecule, so that human 1-39 has a longer duration of action than 1-24 (Baumann and Felber, 1976). Hofmann et al. (1970) also published results showing partial agonist activity of ACTH1-23 and 5Gln-ACTH1-20 in adrenal stimulation assays: 91% and 80% respectively in comparison to ACTH1-24 as control.
- ACTH may also bind the other melanocortin receptors, ie, MC1r, MC3r, MC4r and MC5r, although it is a less potent agonist at these receptors than some of the smaller length melanocortin peptides.
- The term “ACTH analog” or “analog of ACTH” refers to any compounds in which one or more atoms, functional groups, or substructures or amino acids, particularly conservative amino acid substitutions, in ACTH or fragments of ACTH have been replaced with different atoms, groups, or substructures or amino acids, or substitution of L-stereoisomers with D-stereoisomers of the amino acids while retaining the functional activity of the ACTH or fragments of ACTH. In some embodiments, an ACTH analog is a peptide segment of ACTH1-39 peptide that retains biological activity of ACTH.
- The term “ACTH complex” refers to ACTH or fragments or analogs thereof that are optionally complexed with other proteins (e.g., Bovine Serum Albumin) or metal ions, or fragments of ACTH, or any other suitable complexes that retain the functional characteristics of ACTH or ACTH fragments or analogs thereof and/or allow for formulation of ACTH or ACTH fragments or analogs thereof into suitable dosage forms.
- The term “prodrug” refers to a precursor molecule that is a derivative of ACTH or ACTH fragments or analogs thereof that is suitable for incorporation in any dosage form described herein. A “prodrug” refers to a precursor compound that is converted into active compound in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. In some embodiments, prodrugs facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial. As non-limiting examples, a prodrug of ACTH or fragment of analog thereof is metabolically stable and is not degraded in the stomach.
- Prodrugs are generally drug precursors that, following administration to a subject and subsequent absorption, are converted to an active, or a more active species via some process, such as conversion by a metabolic pathway. Some prodrugs have a chemical group present on the prodrug that renders it less active and/or less labile and/or confers solubility or some other property to the drug. Once the chemical group has been cleaved and/or modified from the prodrug the active drug is generated. In some embodiments, a prodrug of ACTH or fragment or analog thereof is an alkyl ester of the parent compound such as, for example, methyl ester, ethyl ester, n-propyl ester, iso-propyl ester, n-butyl ester, sec-butyl ester, tert-butyl ester or any other ester.
- “U”, when appended to dosage amounts, designates a standardized unit of biologic activity as measured by the USP assay for repository corticotropin injection, which provides uniformity of dosing of a hormone peptide, and is expressed as the standardized units of activity per mL, such as, for example, 80 U/mL.
- Provided herein are methods of preventing or treating ARDS comprising administration of adrenocorticotropic hormone (ACTH) peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, as described herein, to individuals in need thereof. In some embodiments, methods of treatment of ARDS described herein allow for down-regulation of systemic inflammation and/or restoration of tissue homeostasis. In some embodiments, provided herein are methods of treatment of lung dysfunction in patients with PaO2/FiO2=100-199 comprising administration of adrenocorticotropic hormone (ACTH) peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, as described herein, to individuals in need thereof. In some embodiments, provided herein are methods of treatment of lung dysfunction in patients with PaO2/FiO2<100 comprising administration of adrenocorticotropic hormone (ACTH) peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, as described herein, to individuals in need thereof.
- In some embodiments, provided herein is a method of treating an individual diagnosed with or suspected of having, or preventing in an individual at risk for developing, acute respiratory distress syndrome (ARDS) comprising administration of a therapeutically effective amount of an adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof, provided that the adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, does not comprise α-MSH.
- In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, may be administered as a first dose, followed by one or more subsequent doses. In some embodiments of the methods of treatment of ARDS described herein, the first dose and one or more subsequent doses of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, are administered in a dosing regimen that is not continuous (e.g., the intervals between doses are uneven). In some embodiments of the methods of treatment of ARDS described above, the first dose and one or more subsequent doses of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, are administered in a dosing regimen that is a continuous dosing regimen. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, may be administered as a first dose, followed by one or more subsequent doses, wherein the subsequent dose values are equivalent to the initial dose value. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, may be administered as a first dose, followed by one or more subsequent doses, wherein the subsequent dose values are not equivalent to the initial dose value. In some embodiments, the first dose is administered upon detection of one or more symptoms of ARDS in a clinically diagnosed ARDS patient. In some embodiments, the one or more subsequent doses are administered every day, every other day, every two days, every three days, every four days, every 5 days, every 6 days, once a week, every two weeks, every three weeks, once a month, every six weeks, every two months, every three months, every four months five months, every six months or any combination thereof. In some embodiments, the one or more subsequent doses are administered within the same day, and the dosing is continued as needed. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof is administered at onset of ARDS and multiple times a day, every day, about every 2 days, about every 5 days, about every week, about every two weeks, about every three weeks, about every month, about every two months, or any combination thereof as needed. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof is administered at one or more intervals during a day, about every day, about every 2 days, about every 5 days, about every week, about every two weeks, about every three weeks, about every month, about every two months, or any combination thereof before onset of ARDS and for as long as the patient experiences ARDS symptoms in the absence of said ACTH peptide or fragment, analog, complex or aggregate thereof.
- In some embodiments, the dose comprises a first phase of dosing of about 4 to about 10 days duration wherein a patient receives a daily dose of 64 U daily or in a divided dose of 32 U administered at a selected interval within each day, followed by one or more subsequent phases of about 4 to about 10 days duration each wherein each successive phase of doses is about 50% of the dose of the preceding phase, and a final phase in which the dose of the preceding phase is administered at intervals of every other day.
- In some embodiments, the dose comprises a first phase of dosing of about 7 days duration wherein the dose is administered as 64 U once per day or 32 U twice a day, followed by a second phase of about 7 days duration wherein the daily, or twice daily, dose is reduced by about 50%, followed by a third phase of about 7 days duration wherein the daily, or twice daily, dose of the second phase is reduced by about 50% and followed by a fourth phase of about 7 days, wherein the dose of the third phase is administered every other day.
- In some embodiments the dose and frequency of dosing are as set out in Table I.
-
TABLE I Day Dose and Frequency 1-7 Administer 64 U once daily 8-14 Decrease administration to 32 U once daily 15-21 Decrease administration to 16 U once daily 22-28 Administer 16 U every other day - In some embodiments the dose and frequency of dosing are as set out in Table II.
-
TABLE II Day Dose and Frequency 1-7 Administer 32U or 16 U in divided doses twice daily 8-14 Decrease administration to 16 U or 8 U in divided doses twice daily 15-21 Administer 16 U or 8 U once daily 22-28 Administer 16 U or 8 U once every other day. - In some embodiments, the dosing regimen comprises doses that produce decreasing levels of drug early in the dosing interval followed by a prolonged dose-free interval. In some embodiments, the dosing regimen comprises a first dose, a series of subsequent doses, followed by a drug holiday, and then, one or more series of doses that are the same as or different from the first series of doses. By way of example only, in one dosing regimen, the methods of treatment of ARDS described above comprise administration of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, and comprise a first dose of 80 U, then a once daily dose of 20 U for three days, followed by a 40 U dose every week for a month, followed by a period of no treatment for 3 months, and then a second series of doses comprising a first dose of 60 U, then a once daily dose of 20 U for three days, followed by a 40 U dose every week for a month, followed by a period of no treatment for 3 months.
- In some embodiments, a dosing regimen comprises dosing that produces escalating levels of drug early in the dosing interval followed by a prolonged dose-free period. By way of example only, in one dosing regimen, the methods of treatment of ARDS describe above comprise administration of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, and comprise a first dose of 20 U, a second dose of 20 U in the same week, then 40 U twice a week, then 40 U every other month for three months.
- In some embodiments, a first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 10 U, 20 U, 30 U, 40 U, 50 U, 60 U, 70 U, 80 U and about 50 U, 60 U, 70 U, 80 U, 90 U, 100 U, 110 U, 120 U, 130 U, 140 U, 150 U or 200 U. In some embodiments, a first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 10 U to about 200 U, between about 10 U to about 150 U, between about 10 U to about 100 U, between about 10 U to about 80 U, between about 10 U to about 60 U, or between about 10 U to about 40 U. In some embodiments, a first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 10 U to about 200 U, between about 20 U to about 200 U, between about 40 U to about 200 U, between about 40 U to about 150 U, between about 40 U to about 100 U, between about 40 U to about 80 U, or between about 40 U to about 60 U. In some embodiments, a first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 20 U to about 200 U, between about 60 U to about 150 U, between about 60 U to about 100 U, or between about 60 U to about 80 U.
- In some embodiments, one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 10 U, 20 U, 30 U, 40 U, 50 U, 60 U, 70 U, 80 U to about 50 U, 60 U, 70 U, 80 U, 90 U, 100 U, 110 U, 120 U, 130 U, 140 U, 150 U or 200 U. In some embodiments, a one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 10 U to about 200 U, between about 10 U to about 150 U, between about 10 U to about 100 U, between about 10 U to about 80 U, between about 10 U to about 60 U, or between about 10 U to about 40 U. In some embodiments, a one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 20 U to about 200 U, between about 20 U to about 150 U, between about 20 U to about 100 U, between about 20 U to about 80 U, or between about 20 U to about 60 U, or between about 20 U to about 40 U. In some embodiments, a one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 40 U to about 200 U, between about 40 U to about 150 U, between about 40 U to about 100 U, between about 40 U to about 80 U, or between about 40 U to about 60 U. In some embodiments, a one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 20 U to about 200 U, between about 60 U to about 150 U, between about 60 U to about 100 U, or between about 60 U to about 80 U.
- In some embodiments, the ACTH, or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered as a synthetic preparation (i.e., not naturally occurring), wherein a first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 10 mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg, 50 mg/kg, 60 mg/kg, 70 mg/kg, 80 mg/kg to about 50 mg/kg, 60 mg/kg, 70 mg/kg, 80 mg/kg, 90 mg/kg, 100 mg/kg, 110 mg/kg, 120 mg/kg, 130 mg/kg, 140 mg/kg, 150 mg/kg or 200 mg/kg. In some embodiments, a first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 10 mg/kg to about 200 mg/kg, between about 20 mg/kg to about 200 mg/kg, between about 20 mg/kg to about 150 mg/kg, between about 20 mg/kg to about 100 mg/kg, between about 20 mg/kg to about 80 mg/kg, between about 20 mg/kg to about 60 mg/kg, or between about 20 mg/kg to about 40 mg/kg. In some embodiments, a first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 40 mg/kg to about 200 mg/kg, between about 40 mg/kg to about 150 mg/kg, between about 40 mg/kg to about 100 mg/kg, between about 40 mg/kg to about 80 mg/kg, or between about 40 mg/kg to about 60 mg/kg. In some embodiments, a first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 20 mg/kg to about 200 mg/kg, between about 60 mg/kg to about 150 mg/kg, between about 60 mg/kg to about 100 mg/kg, or between about 60 mg/kg to about 80 mg/kg.
- Where the ACTH, or fragment, analog, complex or aggregate thereof, or any combination thereof, is a synthetic preparation (i.e., not naturally occurring), in some embodiments, one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 10 mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg, 50 mg/kg, 60 mg/kg, 70 mg/kg, 80 mg/kg to about 50 mg/kg, 60 mg/kg, 70 mg/kg, 80 mg/kg, 90 mg/kg, 100 mg/kg, 110 mg/kg, 120 mg/kg, 130 mg/kg, 140 mg/kg, 150 mg/kg or 200 mg/kg. In some embodiments, one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 10 mg/kg to about 200 mg/kg, between about 10 mg/kg to about 150 mg/kg, between about 10 mg/kg to about 100 mg/kg, between about 10 mg/kg to about 80 mg/kg, between about 10 mg/kg to about 60 mg/kg, or between about 10 mg/kg to about 40 mg/kg. In some embodiments, one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 20 mg/kg to about 200 mg/kg, between about 20 mg/kg to about 150 mg/kg, between about 20 mg/kg to about 100 mg/kg, between about 20 mg/kg to about 80 mg/kg, or between about 20 mg/kg to about 60 mg/kg. In some embodiments, a one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 40 mg/kg to about 200 mg/kg, between about 40 mg/kg to about 150 mg/kg, between about 40 mg/kg to about 100 mg/kg, between about 40 mg/kg to about 80 mg/kg, or between about 40 mg/kg to about 60 mg/kg. In some embodiments a one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 20 mg/kg to about 200 mg/kg, between about 60 mg/kg to about 150 mg/kg, between about 60 mg/kg to about 100 mg/kg, or between about 60 mg/kg to about 80 mg/kg.
- In some embodiments, a first dose of ACTH (e.g., synthetically produced ACTH1-24) or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 0.01 mg to about 10 mg, between about 0.1 mg to about 2.5 mg, between about 0.5 mg to about 1 mg, or between about 2 mg to about 5 mg. In some embodiments, a first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1.0 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3.0 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4.0 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, or about 5 mg.
- In some embodiments, one or more subsequent dose of ACTH (e.g., synthetically produced ACTH1-24) or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 0.01 mg to about 10 mg, between about 0.1 mg to about 2.5 mg, between about 0.5 mg to about 1 mg, or between about 2 mg to about 5 mg. In some embodiments, one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof is about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1.0 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3.0 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4.0 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, or about 5 mg.
- In some embodiments, one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 10% and about 90%, between about 20% and about 80%, between about 20% and about 60%, or between about 20%—and about 40% of the first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof. In some embodiments, one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, is between about 80% and about 200%, between about 80% and about 175%, between about 80% and about 150%, between about 80% and about 125%, between about 80% and about 100%, between about 100% and 200%, between about 100% and 150%, or between about 100% and 120% of the first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof. In some embodiments, one or more subsequent dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof, is 100% of the first dose of ACTH or fragment, analog, complex or aggregate thereof, or any combination thereof.
- In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered to an individual in need thereof in an amount sufficient to provide plasma cortisol secretion levels between about 1.1 to about 10 times 1.1 to about 8 times, 1.1 to about 6 times, 1.1 to about 4 times, between about 1.1 to about 3 times, between about 1.1 to about 2 times, between about 1.1 to about 1.5 times the plasma cortisol secretion levels of a normal individual at about 8 am. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered to an individual in need thereof in an amount sufficient to provide plasma cortisol secretion levels between about 1.5 to about 4 times, between about 1.5 to about 3 times, or between about 1.15 to about 2 times, the plasma cortisol secretion levels of a normal individual at about 8 am.
- In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered to an individual in need thereof in an amount sufficient to provide plasma cortisol secretion levels between about 1.1 to about 10 times 1.1 to about 8 times, 1.1 to about 6 times, 1.1 to about 4 times, between about 1.1 to about 3 times, between about 1.1 to about 2 times, or between about 1.1 to about 1.5 times the plasma cortisol secretion levels prior to administration of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered to an individual in need thereof in an amount sufficient to provide plasma cortisol secretion levels between about 1.5 to about 4 times, between about 1.5 to about 3 times, or between about 1.15 to about 2 times, the plasma cortisol secretion levels prior to administration of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof.
- In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered in an amount sufficient to provide plasma cortisol concentration between about 1.5 to about 120 μg/100 mL over at least 24 hours after administration. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered in an amount sufficient to provide plasma cortisol concentration between about 1.5 to about 60 μg/100 mL over at least 24 hours after administration. In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered in an amount sufficient to provide plasma cortisol concentration between about 1.5 to about 30 μg/100 mL over at least 24 hours after administration.
- In some embodiments, where the patient's condition does not improve upon administration of a dosing regimen described herein, upon the doctor's discretion the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is optionally administered chronically, that is, for an extended period of time, including throughout the duration of the patient's life in order to ameliorate or otherwise control or limit the symptoms of the patients disease or condition.
- In the case wherein the patient's status does improve, upon the doctor's discretion the administration of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof is optionally given continuously; alternatively, the dose of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof being administered is temporarily reduced or temporarily suspended for a certain length of time (i.e., a “drug holiday”). The length of the drug holiday optionally varies between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, or 365 days. The dose reduction during a drug holiday includes from 10%-100%, including, by way of example only, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.
- Once improvement of the patient's conditions has occurred, a maintenance dose is administered if necessary. Subsequently, the dosage or the frequency of administration, or both, is reduced, as a function of the symptoms, to a level at which the improved disease, disorder or condition is retained. In some embodiments, patients require intermittent treatment on a long-term basis upon any recurrence of symptoms.
- In some embodiments, the pharmaceutical compositions described herein are in unit dosage forms suitable for single administration of precise dosages. In unit dosage form, the formulation is divided into unit doses containing appropriate quantities of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof. In some embodiments, the unit dosage is in the form of a package containing discrete quantities of the formulation. Non-limiting examples are packaged tablets or capsules, powders in vials or ampoules, or injectable suspension or solution in ampoules. In some embodiments, aqueous suspension compositions are packaged in single-dose non-reclosable containers. Alternatively, multiple-dose reclosable containers are used. In some of such embodiments, a preservative is optionally included in the composition. By way of example only, formulations for intramuscular injection are presented in unit dosage form, which include, but are not limited to ampoules, or in multi dose containers with a rubber septum or similar structure suitable for withdrawing a dose via syringe and with an added preservative.
- Toxicity and therapeutic efficacy of such therapeutic regimens are optionally determined in cell cultures or experimental animals, including, but not limited to, the determination of the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between the toxic and therapeutic effects is the therapeutic index, which is expressed as the ratio between LD50 and ED50. ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, exhibiting high therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is optionally used in formulating a range of dosage for use in human. The dosage of such ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof lies preferably within a range of circulating concentrations that include the ED50 with minimal toxicity. The dosage optionally varies within this range depending upon the dosage form employed and the route of administration utilized.
- In some embodiments of the methods and dosing regimens described above, ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered in combination with other treatments including, and not limited to, ventilation, mechanical ventilation (including newer modes of mechanical ventilation including, but not limited to, high frequency oscillatory ventilation), a glucocorticoid, a surfactant, inhaled nitric oxide, an antioxidant, a protease inhibitor, a recombinant human activated protein C, a β2-agonist, lisofylline, a statin, inhaled heparin, a diuretic, a sedative, an analgesic, a muscle relaxant, an antibiotic, inhaled prostacyclin, inhaled synthetic prostacyclin analog, ketoconazole, alprostadil, keratinocyte growth factor, beta-agonists, human mAb against TS factor 7a, interferon receptor agonists, insulin, perfluorocarbon, budesonide, recombinant human ACE, recombinant human CC10 protein, tissue plasminogen activator, human mesenchymal stem cells, or nutritional therapy. In other embodiments of combination therapy, the other treatment included is a glucocorticoid, such as, for example, methylprednisolone, dexamethasone, prednisone, prednisolone, betamethasone, triamcinolone, triamcinolone acetonide budesonide, and beclometasone; beta-agonists, such as, for example, albuterol; lisofylline; rosuvastatin, inhaled heparin; inhaled nitric oxide; recombinant human activated protein C; NSAIDS, such as, for example, ibuprofen; naproxen, and acetaminophen; cisatracurium besylate; procysteine; acetylcysteine; inhaled prostacyclin; ketoconazole; alprostadil; keratinocyte growth factor; human mAb against TS factor 7a; insulin; perfluorocarbons, recombinant human ACE; recombinant human CC10 protein; tissue plasminogen activator; human mesenchymal stem cells; or nutritional therapy such as a combination of omega-3 fatty acids, antioxidants, and γ-linolenic acids with isocaloric foods and extracorporeal membrane oxygenation (ECMO).
- NSAIDS include, but are not limited to, aspirin, acetaminophen, diflunisal, salsalate, ibuprofen, dexibuprofen, naproxen, fenoprofen, ketoprofen, dexketoprofen, flurbiprofen, oxaprozin, loxoprofen, indomethacin, tolmetin, sulindac, etodolac, ketorolac, nabumetone, diclofenac, piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam, isoxicam, metenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid, celecoxib, parecoxib, etoricoxib, lumiracoxib, and firocoxib.
- Analgesics include, but are not limited to, NSAIDS and opioids (narcotics). Opioids include, but are not limited to, dextropropoxyphene, codeine, tramadol, tapentadol, anileridine, alphaprodine, pethidine, hydocodone, morphine, oxycodone, methadone, diamorphine, hydromorphone, oxymorphone, levorphanol, 7-hydroxymitragynine, buprenorphine, fentanyl, sufentanil, bromadol, etorphine, dihydroetorphine, and carfentanil. Glucocorticoids include, but are not limited to, hydrocortisone, cortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, beclometasone, or fludrocortisones.
- In some embodiments of combination therapy, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, and the second therapeutic treatment are administered simultaneously. In some embodiments of combination therapy, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, and the second therapeutic treatment are administered serially in any order. In some embodiments of combination therapy, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, and the second therapeutic treatment are administered at different intervals. By way of example only, a second therapeutic treatment is administered after completion of a dosing regimen comprising administration of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof.
- Provided herein, in certain embodiments, are compositions comprising at least one ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, where the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is as described herein.
- Pharmaceutical compositions are formulated using one or more physiologically acceptable carriers including excipients and auxiliaries which facilitate processing of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, into preparations which are used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. A summary of pharmaceutical compositions is found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Ea hston, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa. 1975; Liberman, H. A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins, 1999).
- Provided herein are pharmaceutical compositions that include one or more of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, and a pharmaceutically acceptable diluent(s), excipient(s), or carrier(s). In addition, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is optionally administered as pharmaceutical compositions in which it is mixed with other active ingredients, as in combination therapy. In some embodiments, the pharmaceutical compositions includes other medicinal or pharmaceutical agents, carriers, adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure, and/or buffers. In addition, the pharmaceutical compositions also contain other therapeutically valuable substances.
- A pharmaceutical composition, as used herein, refers to a mixture of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients. In some embodiments, a pharmaceutical composition comprises an ACTH preparation (e.g., an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, and any other proteins and/or other substances that are present in a homogenized pituitary extract obtained from an appropriate animal source) and other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients. The pharmaceutical composition facilitates administration of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, to an organism. In practicing the methods of treatment or use provided herein, an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are administered in a pharmaceutical composition to a mammal having a condition, disease, or disorder to be treated. Preferably, the mammal is a human. The does and dosing regimen varies depending on the severity and stage of the condition, the age and relative health of an individual, the potency of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, used and other factors. The ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is optionally used singly or in combination with one or more therapeutic agents as components of mixtures.
- The pharmaceutical formulations described herein are optionally administered to a individual by multiple administration routes, including but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular, intrathecal), intranasal, buccal, topical, rectal, or transdermal administration routes. The pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.
- The pharmaceutical compositions will include at least one ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, as an active ingredient in free-acid or free-base form, or in a pharmaceutically acceptable salt form. In addition, the methods and pharmaceutical compositions described herein include the use of N-oxides, crystalline forms (also known as polymorphs), as well as active metabolites of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, having the same type of activity. In some situations, ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, exist as tautomers and/or rotational isomers. All tautomers and/or rotational isomers are included within the scope of the embodiments presented herein. Additionally, ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, exists in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. The solvated forms of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, presented herein are also considered to be disclosed herein. In some embodiments, ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, exists as a complex with metal ions, including, for example, Zn+2 ions. The metal-ion complexed forms of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, presented herein are also considered to be disclosed herein.
- “Carrier materials” include any commonly used excipients in pharmaceutics and should be selected on the basis of compatibility with ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, disclosed herein, and the release profile properties of the desired dosage form. Exemplary carrier materials include, e.g., binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, diluents, and the like.
- Moreover, the pharmaceutical compositions described herein, which include a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are formulated into any suitable dosage form, including but not limited to, aqueous oral dispersions, liquids, gels, syrups, elixirs, slurries, suspensions and the like, for oral ingestion by a patient to be treated, solid oral dosage forms, aerosols, controlled release formulations, fast melt formulations, effervescent formulations, lyophilized formulations, tablets, powders, pills, dragees, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate release and controlled release formulations. In some embodiments, a formulation comprising a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a solid drug dispersion. A solid dispersion is a dispersion of one or more active ingredients in an inert carrier or matrix at solid state prepared by the melting (or fusion), solvent, or melting-solvent methods. (Chiou and Riegelman, Journal of Pharmaceutical Sciences, 60, 1281 (1971)). The dispersion of one or more active agents in a solid diluent is achieved without mechanical mixing. Solid dispersions are also called solid-state dispersions. In some embodiments, any ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, described is formulated as a spray dried dispersion (SDD). An SDD is a single phase amorphous molecular dispersion of a drug in a polymer matrix. It is a solid solution prepared by dissolving the drug and a polymer in a solvent (e.g., acetone, methanol or the like) and spray drying the solution. The solvent rapidly evaporates from droplets which rapidly solidifies the polymer and drug mixture trapping the drug in amorphous form as an amorphous molecular dispersion. In some embodiments, such amorphous dispersions are filled in capsules and/or constituted into powders for reconstitution. Solubility of an SDD comprising a drug is higher than the solubility of a crystalline form of a drug or a non-SDD amorphous form of a drug. In some embodiments of the methods described herein, ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are administered as SDDs constituted into appropriate dosage forms described herein.
- Pharmaceutical preparations for oral use are optionally obtained by mixing one or more solid excipient with a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients include, for example, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or others such as: polyvinylpyrrolidone (PVP or povidone) or calcium phosphate. If desired, disintegrating agents are added, such as the cross linked croscarmellose sodium, polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. In some embodiments, a prodrug of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is used in preprations for oral use.
- Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions are generally used, which optionally contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and % or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments are optionally added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
- In some embodiments, the solid dosage forms disclosed herein are in the form of a tablet, (including a suspension tablet, a fast-melt tablet, a bite-disintegration tablet, a rapid-disintegration tablet, an effervescent tablet, or a caplet), a pill, a powder (including a sterile packaged powder, a dispensable powder, or an effervescent powder) a capsule (including both soft or hard capsules, e.g., capsules made from animal-derived gelatin or plant-derived HPMC, or “sprinkle capsules”), solid dispersion, solid solution, bioerodible dosage form, controlled release formulations, pulsatile release dosage forms, multiparticulate dosage forms, pellets, granules, or an aerosol. In other embodiments, the pharmaceutical formulation is in the form of a powder. In still other embodiments, the pharmaceutical formulation is in the form of a tablet, including but not limited to, a fast-melt tablet. Additionally, pharmaceutical formulations of a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are optionally administered as a single capsule or in multiple capsule dosage form. In some embodiments, the pharmaceutical formulation is administered in two, or three, or four, capsules or tablets.
- In another aspect, dosage forms include microencapsulated formulations. In some embodiments, one or more other compatible materials are present in the microencapsulation material. Exemplary materials include, but are not limited to, pH modifiers, erosion facilitators, anti-foaming agents, antioxidants, flavoring agents, and carrier materials such as binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, and diluents.
- Exemplary microencapsulation materials ueful for delaying the release of the formulations including a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, include, but are not limited to, hydroxypropyl cellulose ethers (HPC) such as KLUCEL® (hydroxypropylcellulose) or Nisso HPC, low-substituted hydroxypropyl cellulose ethers (L-HPC), hydroxypropyl methyl cellulose ethers (HPMC) such as Seppifilm-LC, PHARMACOAT® (hypromellose), METOLOSE SR (hypromellose), METHOCEL®-E (cellulose ethers, OPADRY® YS (one step film coating system), PrimaFlo, Benecel MP824, and Benecel MP843, methylcellulose polymers such as METHOCEL®-A (cellulose ethers), hydroxypropylmethylcellulose acetate stearate AQOAT® (HF-LS, HF-LG, HF-MS) and METOLOSE® (methylcellulose; hypromellose), Ethylcelluloses (EC) and mixtures thereof such acs E461, ETHOCEL® (ethylcellulose polymers), AQUALINE®-EC (ethylcellulose), SURELEASE® (ethylcellulose disperson), Polyvinyl alcohol (PVA) such as OPADRY® AMB (aqueous moisture barrier film coating system), hydroxyethylcelluloses such as NATROSOL®, carboxymethylcelluloses and salts of carboxymethylcelluloses (CMC) such as AQUALON®-CMC, polyvinyl alcohol and polyethylene glycol co-polymers such as KOLLICOAT IR® (ethylene glycol and vinyl alcohol graft copolymer) monoglycerides (MYVEROL®), triglycerides (KLX®), polyethylene glycols, modified food starch, acrylic polymers and mixtures of acrylic polymers with cellulose ethers such as EUDRAGIT® EPO (DIMETHYLAMINOETHYL METHACRYLATE COPOLYMER), EUDRAGIT® L30D-55, EUDRAGIT® FS 30D EUDRAGIT® L100-55, EUDRAGIT® L100, EUDRAGIT® S100, EUDRAGIT® RD100, EUDRAGIT® E100, EUDRAGIT® L12.5, EUDRAGIT® S 12.5, EUDRAGIT® NE30D, and EUDRAGIT® NE 40D, cellulose acetate phthalate, sepifilms such as mixtures of HPMC and stearic acid, cyclodextrins, and mixtures of these materials.
- The pharmaceutical solid oral dosage forms including formulations described herein, which include a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are optionally further formulated to provide a controlled release of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof. Controlled release refers to the release of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, from a dosage form in which it is incorporated according to a desired profile over an extended period of time. Controlled release profiles include, for example, sustained release, prolonged release, pulsatile release, and delayed release profiles. In contrast to immediate release compositions, controlled release compositions allow delivery of an agent to a individual over an extended period of time according to a predetermined profile. Such release rates provide levels of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, for an extended period of time and thereby provide a longer period of pharmacologic response while minimizing side effects as compared to conventional rapid release dosage forms. Such longer periods of response provide for many inherent benefits that are not achieved with the corresponding short acting, immediate release preparations. In some embodiments, the formulations described herein, which include a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are delivered using an implant. In some embodiments, the implants are formulated to provide a controlled release of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof. In some embodiments, the implant is an erodible implant.
- In other embodiments, the formulations described herein, which include a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are delivered using a pulsatile dosage form. A pulsatile dosage form is capable of providing one or more immediate release pulses at predetermined time points alter a controlled lag time or at specific sites. Pulsatile dosage forms including the formulations described herein, which include a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are optionally administered using a variety of pulsatile formulations that include, but are not limited to, those described in U.S. Pat. Nos. 5,011,692, 5,017,381, 5,229,135, and 5,840,329. Other pulsatile release dosage forms suitable for use with the present formulations include, but are not limited to, for example, U.S. Pat. Nos. 4,871,549, 5,260,068, 5,260,069, 5,508,040, 5,567,441 and 5,837,284.
- Liquid formulation dosage forms for oral administration are optionally aqueous suspensions selected from the group including, but not limited to, pharmaceutically acceptable aqueous oral dispersions, emulsions, solutions, elixirs, gels, and syrups. See, e.g., Singh et al., Encyclopedia of Pharmaceutical Technology, 2nd Ed., pp. 754-757 (2002). In addition to the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, the liquid dosage forms optionally include additives, such as: (a) disintegrating agents; (b) dispersing agents; (c) wetting agents; (d) at least one preservative, (e) viscosity enhancing agents, (f) at least one sweetening agent, and (g) at least one flavoring agent. In some embodiments, the aqueous dispersions further includes a crystal-forming inhibitor.
- In some embodiments, the pharmaceutical formulations described herein are self-emulsifying drug delivery systems (SEDDS). Emulsions are dispersions of one immiscible phase in another, usually in the form of droplets. Generally, emulsions are created by vigorous mechanical dispersion. SEDDS, as opposed to emulsions or microemulsions, spontaneously form emulsions when added to an excess of water without any external mechanical dispersion or agitation. An advantage of SEDDS is that only gentle mixing is required to distribute the droplets throughout the solution. Additionally, water or the aqueous phase is optionally added just prior to administration, which ensures stability of an unstable or hydrophobic active ingredient. Thus, the SEDDS provides an effective delivery system for oral and parenteral delivery of hydrophobic active ingredients. In some embodiments, SEDDS provides improvements in the bioavailability of hydrophobic active ingredients. Methods of producing self-emulsifying dosage forms include, but are not limited to, for example, U.S. Pat. Nos. 5,858,401, 6,667,048, and 6,960,563.
- Suitable intranasal formulations include those described in, for example, U.S. Pat. Nos. 4,476,116, 5,116,817 and 6,391,452. Nasal dosage forms generally contain large amounts of water in addition to the active ingredient. Minor amounts of other ingredients such as pH adjusters, emulsifiers or dispersing agents, preservatives, surfactants, gelling agents, or buffering and other stabilizing and solubilizing agents are optionally present.
- For administration by inhalation, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is optionally in a form as an aerosol, a mist or a powder. Pharmaceutical compositions described herein are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit is determined by providing a valve to deliver a metered amount. Capsules and cartridges of, such as, by way of example only, gelatin for use in an inhaler or insufflator are formulated containing a powder mix of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, and a suitable powder base such as lactose or starch.
- Buccal formulations that include an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, include, but are not limited to, U.S. Pat. Nos. 4,229,447, 4,596,795, 4,755,386, and 5,739,136. In addition, the buccal dosage forms described herein optionally further include a bioerodible (hydrolysable) polymeric carrier that also serves to adhere the dosage form to the buccal mucosa. The buccal dosage form is fabricated so as to erode gradually over a predetermined time period, wherein the delivery of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is provided essentially throughout. Buccal drug delivery avoids the disadvantages encountered with oral drug administration, e.g., slow absorption, degradation of the active agent by fluids present in the gastrointestinal tract and/or first-pass inactivation in the liver. The bioerodible (hydrolysable) polymeric carrier generally comprises hydrophilic (water-soluble and water-swellable) polymers that adhere to the wet surface of the buccal mucosa. Examples of polymeric carriers useful herein include acrylic acid polymers and co, e.g., those known as “carbomers” (CARBOPOL®, which may be obtained from B.F. Goodrich, is one such polymer). Other components also be incorporated into the buccal dosage forms described herein include, but are not limited to, disintegrants, diluents, binders, lubricants, flavoring, colorants, preservatives, and the like. For buccal or sublingual administration, the compositions optionally take the form of tablets, lozenges, or gels formulated in a conventional manner.
- Transdermal formulations of a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are administered for example by those described in U.S. Pat. Nos. 3,598,122, 3,598,123, 3,710,795, 3,731,683, 3,742,951, 3,814,097, 3,921,636, 3,972,995, 3,993,072, 3,993,073, 3,996,934, 4,031,894, 4,060,084, 4,069,307, 4,077,407, 4,201,211, 4,230,105, 4,292,299, 4,292,303, 5,336,168, 5,665,378, 5,837,280, 5,869,090, 6,923,983, 6,929,801 and 6,946,144.
- The transdermal formulations described herein include at least three components: (1) a formulation of a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof; (2) a penetration enhancer; and (3) an aqueous adjuvant. In addition, transdermal formulations include components such as, but not limited to, gelling agents, creams and ointment bases, and the like. In some embodiments, the transdermal formulation further includes a woven or non-woven backing material to enhance absorption and prevent the removal of the transdermal formulation from the skin. In other embodiments, the transdermal formulations described herein maintain a saturated or supersaturated state to promote diffusion into the skin.
- In some embodiments, formulations suitable for transdermal administration of a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, employ transdermal delivery devices and transdermal delivery patches and are lipophilic emulsions or buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an adhesive. Such patches are optionally constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents. Still further, transdermal delivery of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is optionally accomplished by means of iontophoretic patches and the like. Additionally, transdermal patches provide controlled delivery of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof. The rate of absorption is optionally slowed by using rate-controlling membranes or by trapping the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, within a polymer matrix or gel. Conversely, absorption enhancers are used to increase absorption. An absorption enhancer or carrier includes absorbable pharmaceutically acceptable solvents to assist passage through the skin. For example, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, optionally with carriers, optionally a rate controlling barrier to deliver the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
- Formulations that include a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, suitable for intramuscular, intrathecal, subcutaneous, or intravenous injection include physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and non-aqueous carriers, diluents, solvents, or vehicles including water, ethanol, polyols (propyleneglycol, polyethylene-glycol, glycerol, cremophor and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity is maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Formulations suitable for subcutaneous injection also contain optional additives such as preserving, wetting, emulsifying, and dispensing agents.
- For intravenous injections, a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is optionally formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer. Alternatively, a ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is optionally formulated as a sterile powder for reconstitution into sterile solutions or dispersions for intravenous delivery. These ready-made or reconstituted solutions or dispersions for intravenous delivery can be packaged in sterile bags for intravenous drip. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. For other parenteral injections including intrathecal and intramuscular injections, appropriate formulations include aqueous or nonaqueous solutions, preferably with physiologically compatible buffers or excipients.
- Parenteral injections optionally involve bolus injection or continuous infusion. Formulations for injection are optionally presented in unit dosage form, e.g., in ampoules or in multi dose containers, with an added preservative. In some embodiments, the pharmaceutical composition described herein are in a form suitable for parenteral injection as a sterile suspensions, solutions or emulsions in oily or aqueous vehicles, and contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Pharmaceutical formulations for parenteral administration include aqueous solutions of the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, in water soluble form, optionally including a gelling agent. Additionally, an ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, may be prepared as a lyophilized powder for reconstitution with a physiologically suitable diluent.
- In some embodiments, the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered topically and formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams or ointments. Such pharmaceutical compositions optionally contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
- The ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is also optionally formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas, containing conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, PEG, and the like. In suppository forms of the compositions, a low-melting wax such as, but not limited to, a mixture of fatty acid glycerides, optionally in combination with cocoa butter is first melted.
- Male Wistar rats weighing 200-250 g are anesthetized by i.p. injection of 125 mg/kg ketamine. Tracheotomy is performed on all animals which are then subdivided into three groups (n=10) to receive i.t. saline (sham, group A); i.t. bleomycin and control treatment (group B); or i.t. bleomycin and active treatment (group C). The neck wound is closed, and the animals are returned to their cages and allowed free access to food and water.
- Two hundred microliters of sterile saline (group A, sham) or 1 mg of bleomycin sulfate in 200 μL of sterile saline (groups B and C) are instilled into the lungs using a 25-gauge needle inserted between the cartilaginous rings of the trachea. Ten of the bleomycin-instilled animals receive an i.p. injection of 0.5 mL saline (group B). Ten of the bleomycin recipients are assigned to active treatment (group C) and receive i.p. injections of ACTH in 0.5 mL saline. Saline or ACTH are injected immediately before bleomycin instillation.
- Five rats from each group (n=15) are anesthetized by ketamine at 8 h. A xiphopubic incision is done to expose the inferior vena cava and the lungs. Blood is collected from the inferior vena cava in heparinized syringes. The other animals are killed using the same procedure at 24 h; these rats receive a second i.p. injection of ACTH or saline at 12 h. Longitudinal sections of lung tissue are obtained from the right lung and a) are snap frozen in liquid nitrogen for RNA extraction, b) or are fixed in formalin and paraffin embedded for histology and immunohistochemistry. Left lungs are used to determine wet/dry (W/D) weight ratio.
- Circulating NO is measured as an index of systemic inflammation. Lung edema is evaluated through histological examination and calculation of the W/D weight ratio. The frozen lung samples are used to obtain a gene expression profile to evaluate stress and inflammatory response.
- Three groups of rats (n=10 each) receive: intratracheal infusion of endotoxin (S. typhosa, 500 mg in 0.25 mL saline solution) plus i.p. injections of ACTH (in 0.2 mL solution) at 0, 2, and 4 hours postendotoxin treatment; intratracheal endoxin infusion plus saline injections; control intratracheal saline infusion plus saline injections.
- Six hours after endotoxin administration the trachea is cannulated and the cannula is secured with silk thread. Cell medium (12 mL) is used to wash the pulmonary tree (injected and withdrawn five times); both the bronchoalveolar lavage (BAL) fluid and whole blood from the jugular vein are transferred to test tubes for analysis in a cell counter.
- Therapeutic effect of ACTH on white blood cell (WBC) migration is assessed through comparison of WBC counts in BAL fluid and the blood.
- Purpose:
- A randomized, double-blind, parallel group, placebo-controlled pilot safety and efficacy study compares three dosing regimens of ACTH to Placebo in patients with moderate or severe ARDS (PaO2/FiO2≤200 mmHg with PEEP≥5 cm H2O). A total of ˜130 patients are randomized.
- Screening:
- Patients are eligible for study enrollment if all screening criteria for ARDS are met within the same 24 hour window, and ARDS criteria persist for a minimum of 24 hours and a maximum of 10 days after the initial ARDS diagnosis is made and all inclusion/exclusion criteria are met. Total study duration for each patient including follow-up is approximately 60 days.
- Study Procedure:
- Treatment Period (28 days): At
study Day 0, eligible patients undergo baseline assessments, randomization to treatment group, and the first dose of study medication is administered. Safety, tolerability and efficacy of study medication is assessed as long as the patient remains hospitalized. If a patient is discharged from the hospital prior to Day 28, a home visit occurs on Day 28 (±2 days) to conduct required assessments. - Follow-up Period (32 days): The Follow-Up Period begins immediately after the Treatment Period. Patients do not receive study medication during the Follow-Up Period. Day 60 is the last day of study participation for patients, and safety and efficacy assessments are performed.
- Study Outcome Measures:
- The primary outcome measure is the number of ventilator-free days (patient alive and breathing without assistance for ≥48 hours) by Day 28 after randomization.
- The secondary outcome measures include time to successful liberation from ventilator support, defined as ≥48 hours alive and breathing without assistance (supplemental oxygen support is acceptable); number of organ failure-free days during the first 28 and 60 days; number of ICU-free and hospital free days during the first 28 and 60 days for all patients who survive to ICU and hospital discharge, respectively; change over time in PaO2/FiO2 ratio from baseline (Day 0) during the first 28 days; change over time in Lung Injury Score (LIS) from baseline (Day 0) during the first 28 days; change over time in Systemic Organ Failure Assessment Score (SOFA) score during the first 28 days; and mortality at Day 28 and Day 60.
- Safety Endpoints:
- Safety and tolerability are assessed by treatment-emergent adverse events; physical examinations; laboratory measurements including glycemic status, total daily dose of insulin (TDDI), serum cortisol, hematology, chemistry, and urinalysis; 12-lead electrocardiograms (ECGs); blood pressure (supine) measurement; and heart rate measurement.
- To prepare a parenteral pharmaceutical composition suitable for administration by intramuscular or subcutaneous injection, a water-soluble ACTH peptide or fragment, analog, complex or aggregate or salt thereof, or any combination thereof, for example, a highly purified sterile preparation of an analog of porcine adrenocorticotropic hormone is admixed with 16% gelatin and then dissolved in sterile, non-pyrogenic water for injection with addition of 0.5% phenol, not more than 0.1% cysteine (added), and sodium hydroxide and/or acetic acid as needed to adjust pH. The resulting gel mixture is incorporated into a
multi dosage 5 mL vial of a form suitable for administration by injection, the potency of the composition is measured in USP units (designated as “U” which provides a standardized measure of activity) and a multi-dose vial may provide, for example 80 U/mL - To prepare a pharmaceutical composition for inhalation delivery, 20 mg of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is mixed with 50 mg of anhydrous citric acid and 100 mL of 0.9% sodium chloride solution. The mixture is incorporated into an inhalation delivery unit, such as a nebulizer, which is suitable for inhalation administration.
- To prepare a pharmaceutical composition for rectal delivery, 100 mg of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is mixed with 2.5 g of methylcelluose (1500 mPa), 100 mg of methylparapen, 5 g of glycerin and 100 mL of purified water. The resulting gel mixture is then incorporated into rectal delivery units, such as syringes, which are suitable for rectal administration.
- To prepare a pharmaceutical topical gel composition, 100 mg of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is mixed with 1.75 g of hydroxypropyl celluose, 10 mL of propylene glycol, 10 mL of isopropyl myristate and 100 mL of purified alcohol USP. The resulting gel mixture is then incorporated into containers, such as tubes, which are suitable for topicl administration.
- To prepare a pharmaceutical composition for oral delivery, 100 mg of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, or a prodrug thereof, is mixed with 750 mg of starch. The mixture is incorporated into an oral dosage unit, such as a hard gelatin capsule, which is suitable for oral administration.
- To prepare a pharmaceutical nasal spray solution, 10 g of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is mixed with 30 mL of a 0.05M phosphate buffer solution (pH 4.4). The solution is placed in a nasal administrator designed to deliver 100 μl of spray for each application.
- The objective of this study was to evaluate the effects of porcine ACTH1-39 (pACTH1-39) on in vitro chemotaxis of human neutrophils isolated from the blood of healthy human subjects (n=6) in response to IL-8, a potent neutrophil chemoattractant. Neutrophils play a role in the pathogenesis of ARDS, and the influx of neutrophils is often observed of patients with ARDS. IL-8 (interleukin-8) is a chemotactic factor implicated in the neutrophil recruitment in the lungs of ARDS patients (Clinical Science, 2008, 114, 403-412).
- In this study, neutrophil chemotaxis was evaluated using a Boyden chamber assay. Four concentrations of pACTH1-39 (0.1, 1, 10, 100 μg/mL) were tested in quadruplicate with cells isolated from each neutrophil donor (
FIG. 1 ). Additional studies were performed that confirmed pACTH1-39 did not exhibit cytotoxicity for human neutrophils. Data were analyzed using GraphPad Prism software and nonparametric analysis (Kruskal Wallis with Dunns multiple comparison post hoc tests). The results demonstrated that pACTH1-39 attenuated IL-8 induced neutrophil chemotaxis in vitro. - Granulocyte chemotaxis in vivo was assessed by evaluating the effects of ACTHAR® (adrenocorticotropic hormone) on zymosan-induced peritonitis. In this model, heat-killed yeast particles (zymosan) are injected into the peritoneal cavity of mice. Zymosan activates complement, mast cells and peritoneal macrophages, generates proinflammatory mediators, and induces the migration of leukocytes into the peritoneal cavity. The infiltrating cells are primarily neutrophils, although monocytes also migrate at later time points.
- ACTHAR® (adrenocorticotropic hormone) (160, 400 or 800 U/kg; n=8/group) or placebo gel (10 mL/kg; n=8/group) was administered to
animals 1 hour before zymosan challenge. Separate groups of mice were sacrificed 4 hours and 24 hours post zymosan challenge, and lavage was performed to measure the number and type of leukocytes which migrated into the peritoneal cavity in response to zymosan. Results (FIG. 2 ) were compared to naïve animals not receiving zymosan (n=8/group). Additional groups of mice (not shown) received dexamethasone (1 mg/kg) or the same volume of vehicle control one hour prior to zymosan injection, as corticosteroid therapy serves as a positive control for efficacy in this model. Data were analyzed using GraphPad Prism software and nonparametric analysis (Kruskal Wallis with Dunns multiple comparison post hoc tests). This study demonstrated that ACTHAR® (adrenocorticotropic hormone) attenuated granulocyte chemotaxis in vivo. - This study was performed to evaluate the effects of ACTHAR® (adrenocorticotropic hormone) and placebo gel on IgG production from B cells isolated from healthy normal human subjects (n=5) and to assess effects of ACTHAR® (adrenocorticotropic hormone) on B cell proliferation and viability in response to stimulation with IL4/CD40L. Isolated B cells were cultured for 7 days in replicate cultures with proprietary dilutions of Acthar® or placebo gel, or with dexamethasone, with and without added CD40L/IL-4. Secreted total antibodies (IgG) in culture supernatants were measured using commercial ELISA kits. Data were analyzed using GraphPad Prism software and nonparametric analysis (Kruskal Wallis with Dunns multiple comparison post hoc tests). This results showed that ACTHAR® (adrenocorticotropic hormone) decreased in vitro antibody production after B cell stimulation with IL4/CD40L (
FIG. 3 ). - The objective of this study was to evaluate the effects of ACTHAR® (adrenocorticotropic hormone) and placebo gel on antibody production associated with both new and established antigen-specific immune responses. Mice were immunized with chicken ovalbumin (Ova) on
Day 1 and again onDay 15. Treatment with ACTHAR® (adrenocorticotropic hormone) (160 or 400 U/kg) or placebo gel (5 mL/kg) was initiated either onDay 1, prior to immunization, or onDay 15 prior to immunization boost. Circulating serum anti Ova IgG1 levels were measured by ELISA on Day 15 (not shown) andDay 29. Eight animals were studied per group for each treatment and condition. Data were analyzed using GraphPad Prism software and nonparametric analysis (Kruskal Wallis with Dunns multiple comparison post hoc tests). This study showed that ACTHAR® (adrenocorticotropic hormone) attenuated antigen-specific antibody production in vivo (FIG. 4 ). - This study was performed to evaluate the effects of porcine ACTH1-39 (pACTH1-39 supplied by Bachem. Del.), in an in vitro cell model of fibrosis. pACTH1-39 was tested for its ability to inhibit TGFβ1-induced differentiation of normal human lung fibroblasts (NHLF) into fibrogenic myofibroblasts producing extracellular matrix (collagen). At
day 1 the cells were seeded, at day 2 FBS medium was changed from 10% FBS to 0.1% FBS, atday 3 the medium was replaced with fresh medium and stimuli and different treatment concentrations were added to the cells, and at day 7 the cells were collected and analyzed for matrix protein content. - The matrix protein content in the culture medium was determined at
day 4, and was measured using a Sirius Red based assay (soluble collagen assay kit from QuickZyme). The values were expressed in μg matrix protein per well (based on a collagen standard). Data were analyzed using GraphPad Prism software and nonparametric analysis (Kruskal Wallis with Dunns multiple comparison post hoc tests). The results demonstrated that pACTH1-39 attenuated in vitro lung-specific fibrogenic potential (FIG. 5 ). - Patients with ARDS typically have increased levels of inflammatory mediators such as IL-6 and IL-8 in lung lining fluid as well as in the circulation. High titer of autoantibodies to a number of cytokines have also been detected. These antibodies may be biomarkers for the high levels of cytokines which may cause autoimmunization and possibly contribute to immune dysfunction observed in ARDS (Journal of Translational Medicine, 2010, 8, 97). ARDS is associated with high capillary alveolar permeability to proteins (Crit. Care Med., 2001, 29, 10). Different strategies have been developed in order to reproduce the features of human ARDS in animals. One such strategy for modeling the disease is to injure the lung directly by a noxious stimulus, including the intratracheal or intranasal administration of bacteria or bacterial products such as LPS, since intra- or extra-pulmonary sepsis is the most common risk factor for the development of ARDS.
- An in vivo model was used to evaluate ACTHAR® (adrenocorticotropic hormone) gel as a potential treatment for human ARDS. A single IT instillation of LPS (4 mg/kg) was administered to Sprague Dawley rats (˜250 g, 8-9 weeks of age) to induce lung injury. Following LPS-instillation, placebo gel or ACTHAR® (adrenocorticotropic hormone) gel was administered subcutaneously either daily (placebo gel or 160 U/kg ACTHAR® (adrenocorticotropic hormone) gel) or twice daily (80 U/kg ACTHAR® (adrenocorticotropic hormone) gel) for up to 14 days. Separate groups of rats (n=6) were sacrificed on
Days body weight ratio Days 1 and 2 post IT LPS), no significant differences in these outcome measures were observed (data not shown). This series of experiments showed that ACTHAR® (adrenocorticotropic hormone) increased the number of animals with no abnormal clinical phenotype after LPS-induced acute lung injury (FIG. 6 ), that ACTHAR® (adrenocorticotropic hormone) attenuated edema formation after LPS-induced acute lung injury (FIG. 7 ), that ACTHAR® (adrenocorticotropic hormone) attenuated alveolo-capillary permeability following LPS-induced acute lung injury (FIG. 8 ), and that ACTHAR® (adrenocorticotropic hormone) attenuated airspace inflammation after LPS-induced acute lung injury (FIG. 9 ). -
- Hofmann, et al. P.N.A.S., Vol. 67, No. 2, pp. 829-836, October 1970.
- Johnson, et al., Acute Lung Injury: Epidemiology, Pathogenesis, and Treatment J Aerosol Med Pulm Drug Deliv. August 2010; 23(4): 243-252
- Ware L B, Matthay M A. The acute respiratory distress syndrome. N
Engl J Med 2000; 342:1334-49 - Cushing's Syndrome (Monographs on Endocrinology) Volume 22, 1982, pp 23-32
- CH. 3. ACTH Action Dorothy T. Krieger M. D.
- While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Claims (23)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/251,363 US20190160150A1 (en) | 2013-03-14 | 2019-01-18 | Acth for treatment of acute respiratory distress syndrome |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361785631P | 2013-03-14 | 2013-03-14 | |
US14/214,449 US10232018B2 (en) | 2013-03-14 | 2014-03-14 | ACTH for treatment of acute respiratory distress syndrome |
US16/251,363 US20190160150A1 (en) | 2013-03-14 | 2019-01-18 | Acth for treatment of acute respiratory distress syndrome |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/214,449 Continuation US10232018B2 (en) | 2013-03-14 | 2014-03-14 | ACTH for treatment of acute respiratory distress syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190160150A1 true US20190160150A1 (en) | 2019-05-30 |
Family
ID=50631086
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/214,449 Active 2034-06-08 US10232018B2 (en) | 2013-03-14 | 2014-03-14 | ACTH for treatment of acute respiratory distress syndrome |
US16/251,363 Abandoned US20190160150A1 (en) | 2013-03-14 | 2019-01-18 | Acth for treatment of acute respiratory distress syndrome |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/214,449 Active 2034-06-08 US10232018B2 (en) | 2013-03-14 | 2014-03-14 | ACTH for treatment of acute respiratory distress syndrome |
Country Status (3)
Country | Link |
---|---|
US (2) | US10232018B2 (en) |
EP (1) | EP2968475A2 (en) |
WO (1) | WO2014153221A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11975047B1 (en) | 2022-10-28 | 2024-05-07 | Ani Pharmaceuticals, Inc. | Methods for storing and warming purified corticotropin compositions |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10232018B2 (en) | 2013-03-14 | 2019-03-19 | Mallinckrodt Ard Ip Limited | ACTH for treatment of acute respiratory distress syndrome |
US9688754B2 (en) | 2014-02-20 | 2017-06-27 | Alder Biopharmaceuticals, Inc. | Anti-ACTH antibodies and use thereof |
US11338018B2 (en) | 2016-12-19 | 2022-05-24 | Harrow Ip, Llc | Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof |
WO2020150262A1 (en) * | 2019-01-17 | 2020-07-23 | Harrow Ip, Llc | Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof |
EP3911360A4 (en) * | 2019-01-18 | 2022-09-21 | Mallinckrodt Ard IP Unlimited Company | Methods of modulating corticosteroid response |
US20210322520A1 (en) * | 2019-01-18 | 2021-10-21 | Mallinckrodt Ard Ip Unlimited Company | Methods of modulating corticosteroid response |
US11752199B1 (en) * | 2020-02-25 | 2023-09-12 | Mallinckrodt Ard Ip Unlimited Company | Methods of modulating pericytes |
CN117106057A (en) * | 2022-08-19 | 2023-11-24 | 南京汉欣医药科技有限公司 | High-purity human adrenocorticotropic hormone or analogue thereof and large-scale preparation method thereof |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3993073A (en) | 1969-04-01 | 1976-11-23 | Alza Corporation | Novel drug delivery device |
US3598122A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
US4069307A (en) | 1970-10-01 | 1978-01-17 | Alza Corporation | Drug-delivery device comprising certain polymeric materials for controlled release of drug |
US3731683A (en) | 1971-06-04 | 1973-05-08 | Alza Corp | Bandage for the controlled metering of topical drugs to the skin |
US3742951A (en) | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
US3996934A (en) | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
BE795384A (en) | 1972-02-14 | 1973-08-13 | Ici Ltd | DRESSINGS |
US3921636A (en) | 1973-01-15 | 1975-11-25 | Alza Corp | Novel drug delivery device |
US3993072A (en) | 1974-08-28 | 1976-11-23 | Alza Corporation | Microporous drug delivery device |
US3972995A (en) | 1975-04-14 | 1976-08-03 | American Home Products Corporation | Dosage form |
US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4031894A (en) | 1975-12-08 | 1977-06-28 | Alza Corporation | Bandage for transdermally administering scopolamine to prevent nausea |
US4060084A (en) | 1976-09-07 | 1977-11-29 | Alza Corporation | Method and therapeutic system for providing chemotherapy transdermally |
US4201211A (en) | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
JPS5562012A (en) | 1978-11-06 | 1980-05-10 | Teijin Ltd | Slow-releasing preparation |
US4230105A (en) | 1978-11-13 | 1980-10-28 | Merck & Co., Inc. | Transdermal delivery of drugs |
US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
US4291015A (en) | 1979-08-14 | 1981-09-22 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing a vasodilator |
US5116817A (en) | 1982-12-10 | 1992-05-26 | Syntex (U.S.A.) Inc. | LHRH preparations for intranasal administration |
US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
EP0230654B1 (en) | 1985-12-28 | 1992-03-18 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
US5633009A (en) | 1990-11-28 | 1997-05-27 | Sano Corporation | Transdermal administration of azapirones |
US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
US5665378A (en) | 1994-09-30 | 1997-09-09 | Davis; Roosevelt | Transdermal therapeutic formulation |
US5567441A (en) | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
US6929801B2 (en) | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
US6923983B2 (en) | 1996-02-19 | 2005-08-02 | Acrux Dds Pty Ltd | Transdermal delivery of hormones |
US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
US5869090A (en) | 1998-01-20 | 1999-02-09 | Rosenbaum; Jerry | Transdermal delivery of dehydroepiandrosterone |
US6946144B1 (en) | 1998-07-08 | 2005-09-20 | Oryxe | Transdermal delivery system |
CA2439691A1 (en) | 2001-03-02 | 2002-09-12 | Bristol-Myers Squibb Company | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
US6960563B2 (en) | 2001-08-31 | 2005-11-01 | Morton Grove Pharmaceuticals, Inc. | Spontaneous emulsions containing cyclosporine |
PL1751273T3 (en) | 2004-04-08 | 2011-07-29 | Astellas Pharma Inc | Compound ws727713 |
CA3044795A1 (en) | 2005-07-08 | 2007-01-18 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands |
WO2008033395A2 (en) * | 2006-09-14 | 2008-03-20 | Biorexis Pharmaceutical Corporation | Melanocortin and transferrin fusion proteins |
EP2081587A2 (en) * | 2006-10-18 | 2009-07-29 | Research Development Foundation | Alpha-msh therapies for treatment of autoimmune disease |
US8563000B2 (en) | 2007-05-25 | 2013-10-22 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
RU2010114006A (en) * | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | APPLICATION OF A PEPTIDE AS A THERAPEUTIC |
US20130259875A1 (en) * | 2010-05-11 | 2013-10-03 | Questcor Pharmaceuticals, Inc. | Acth for treatment of amyotrophic lateral sclerosis |
US10232018B2 (en) | 2013-03-14 | 2019-03-19 | Mallinckrodt Ard Ip Limited | ACTH for treatment of acute respiratory distress syndrome |
-
2014
- 2014-03-14 US US14/214,449 patent/US10232018B2/en active Active
- 2014-03-14 EP EP14721142.9A patent/EP2968475A2/en not_active Withdrawn
- 2014-03-14 WO PCT/US2014/029695 patent/WO2014153221A2/en active Application Filing
-
2019
- 2019-01-18 US US16/251,363 patent/US20190160150A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11975047B1 (en) | 2022-10-28 | 2024-05-07 | Ani Pharmaceuticals, Inc. | Methods for storing and warming purified corticotropin compositions |
Also Published As
Publication number | Publication date |
---|---|
EP2968475A2 (en) | 2016-01-20 |
US20140322226A1 (en) | 2014-10-30 |
US10232018B2 (en) | 2019-03-19 |
WO2014153221A2 (en) | 2014-09-25 |
WO2014153221A3 (en) | 2014-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190160150A1 (en) | Acth for treatment of acute respiratory distress syndrome | |
US20180250365A1 (en) | Acth for treatment of amyotrophic lateral sclerosis | |
US10722513B2 (en) | Treatment of respiratory diseases | |
De Luca et al. | Pharmacological therapies for pediatric and neonatal ALI/ARDS: an evidence-based review | |
JP2017524663A (en) | PPAR compounds used for the treatment of fibrotic diseases | |
US20220347189A1 (en) | Methods of treating eosinophilic esophagitis and reducing candidiasis | |
US20230173031A1 (en) | Thymosin alpha 1 for use in treatment of cystic fibrosis | |
US20190216901A1 (en) | Acth prophylactic treatment of renal disorders | |
Saad et al. | The role of vasopressin and the vasopressin type V1a receptor agonist selepressin in septic shock | |
EP3884945A1 (en) | Glutarimide derivative for overcoming resistance to steriods | |
US11439631B2 (en) | Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines | |
US10624883B2 (en) | Pulmonary hypertension preventative or therapeutic agent containing component exhibiting selenoprotein P activity-inhibiting effect | |
EP3402505B1 (en) | Pharmaceutical formulations for the treatment of diabetes | |
RU2737799C1 (en) | Inhaled hexapeptide for treating respiratory diseases associated with interleukin-6 | |
ES2932076T3 (en) | Nonsteroidal Selective Glucocorticoid Receptor Agonist Modulators (SEGRAMs) and Uses Thereof | |
CN114569623A (en) | Application of hydroxyprogesterone caproate in preparing medicine for treating interstitial pneumonia | |
KR20180065223A (en) | A pharmaceutical composition for treating or alleviating asthma | |
EP3700513B1 (en) | Non-steroidal selective glucocorticoid receptor agonistic modulators (segrams) and uses thereof | |
RU2667466C1 (en) | Peptide compound, restoring function of respiratory bodies and inflammable immunomodulating action | |
WO2021211006A1 (en) | Inhaled hexapeptide for treating interleukin-6 related respiratory diseases | |
KR20120116421A (en) | Use of inhalable powder formulation comprising growth hormone for preventing or treating nmda receptor hypofunction-related diseases | |
BR112021007140A2 (en) | mucoadhesive pharmaceutical compositions of corticosteroids | |
Kamada et al. | Glucocorticoids: of asthma for many years and are |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AG Free format text: NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY;ASSIGNOR:MALLINCKRODT ARD IP LIMITED;REEL/FRAME:049821/0425 Effective date: 20190719 |
|
AS | Assignment |
Owner name: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LI Free format text: SECURITY INTEREST;ASSIGNORS:MALLINCKRODT ARD IP LIMITED;MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED;SPECGX LLC;AND OTHERS;REEL/FRAME:051256/0829 Effective date: 20191209 Owner name: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT, DELAWARE Free format text: SECURITY INTEREST;ASSIGNORS:MALLINCKRODT ARD IP LIMITED;MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED;SPECGX LLC;AND OTHERS;REEL/FRAME:051256/0829 Effective date: 20191209 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: VTESSE LLC (F/K/A VTESSE INC.), MISSOURI Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:060389/0839 Effective date: 20220616 Owner name: STRATATECH CORPORATION, WISCONSIN Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:060389/0839 Effective date: 20220616 Owner name: SPECGX LLC, MISSOURI Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:060389/0839 Effective date: 20220616 Owner name: MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY), IRELAND Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:060389/0839 Effective date: 20220616 Owner name: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED), IRELAND Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:060389/0839 Effective date: 20220616 Owner name: MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED), IRELAND Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:060389/0839 Effective date: 20220616 Owner name: MALLINCKRODT LLC, MISSOURI Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:060389/0839 Effective date: 20220616 Owner name: OCERA THERAPEUTICS, INC., MISSOURI Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:060389/0839 Effective date: 20220616 |
|
AS | Assignment |
Owner name: INO THERAPEUTICS LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: IKARIA THERAPEUTICS LLC, NEW JERSEY Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: THERAKOS, INC., MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: ST SHARED SERVICES LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: INFACARE PHARMACEUTICAL CORPORATION, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.), IRELAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED, IRELAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: VTESSE LLC (F/K/A VTESSE INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: SUCAMPO PHARMA AMERICAS LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: STRATATECH CORPORATION, WISCONSIN Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: SPECGX LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED), IRELAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED), IRELAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: MEH, INC., MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: IMC EXPLORATION COMPANY, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: MALLINCKRODT US HOLDINGS LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: MALLINCKRODT VETERINARY, INC., MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: LIEBEL-FLARSHEIM COMPANY LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: LAFAYETTE PHARMACEUTICALS LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: MALLINCKRODT LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: MALLINCKRODT ENTERPRISES LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: CNS THERAPEUTICS, INC., MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: LUDLOW LLC (F/K/A LUDLOW CORPORATION), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: MNK 2011 LLC (F/K/A MALLINCKRODT INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: MALLINCKRODT US POOL LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: MALLINCKRODT CARRIBEAN, INC., MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: MALLINCKRODT FINANCE GMBH, SWITZERLAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: MALLINCKRODT CB LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 Owner name: MALLINCKRODT INTERNATIONAL FINANCE S.A., LUXEMBOURG Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049821, FRAME 0425;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0176 Effective date: 20231114 |